<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Burns Trauma</journal-id><journal-id journal-id-type="iso-abbrev">Burns Trauma</journal-id><journal-title-group><journal-title>Burns &#x00026; Trauma</journal-title></journal-title-group><issn pub-type="ppub">2321-3868</issn><issn pub-type="epub">2321-3876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27574685</article-id><article-id pub-id-type="pmc">4964041</article-id><article-id pub-id-type="publisher-id">40</article-id><article-id pub-id-type="doi">10.1186/s41038-016-0040-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The evidence for natural therapeutics as potential anti-scarring agents in burn-related scarring</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mehta</surname><given-names>M.</given-names></name><address><email>manojm@bcom.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Branford</surname><given-names>O. A.</given-names></name><address><email>olivier.branford@icloud.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rolfe</surname><given-names>K. J.</given-names></name><address><phone>0207 435 6464</phone><email>krolfe@bcom.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>British College of Osteopathic Medicine (BCOM), Finchley Road, London, NW3 5HR UK </aff><aff id="Aff2"><label>2</label>The Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ UK </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>4</volume><elocation-id>15</elocation-id><history><date date-type="received"><day>5</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>Though survival rate following severe thermal injuries has improved, the incidence and treatment of scarring have not improved at the same speed. This review discusses the formation of scars and in particular the formation of hypertrophic scars. Further, though there is as yet no gold standard treatment for the prevention or treatment of scarring, a brief overview is included. A number of natural therapeutics have shown beneficial effects both in vivo and in vitro with the potential of becoming clinical therapeutics in the future. These natural therapeutics include both plant-based products such as resveratrol, quercetin and epigallocatechin gallate as examples and includes the non-plant-based therapeutic honey. The review also includes potential mechanism of action for the therapeutics, any recorded adverse events and current administration of the therapeutics used. This review discusses a number of potential &#x02018;treatments&#x02019; that may reduce or even prevent scarring particularly hypertrophic scarring, which is associated with thermal injuries without compromising wound repair.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Burns</kwd><kwd>Hypertrophic scar</kwd><kwd>Natural therapeutics</kwd><kwd>Wound healing</kwd></kwd-group><funding-group><award-group><funding-source><institution>BNOA</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>A burn is defined by the World Health Organisation (WHO) as &#x02018;an injury to the skin or other organic tissue primarily caused by heat or due to radiation, radioactivity, electricity, friction or contact with chemicals&#x02019; [<xref ref-type="bibr" rid="CR1">1</xref>]. It has been estimated that annually, there are 486,000 burn injuries in the USA that required medical attention with 40,000 requiring hospitalisation [<xref ref-type="bibr" rid="CR2">2</xref>], with a global incidence in 2004 of approximately 11 million burn injuries requiring medical attention [<xref ref-type="bibr" rid="CR3">3</xref>]. Non-fatal burns are one of the leading causes of disability in low- to middle-income countries [<xref ref-type="bibr" rid="CR3">3</xref>]. Advances in medical treatment means that survival following extensive burns has improved over recent years though the incidence, treatment and prevention of scarring from thermal injuries has not improved over the same time frame [<xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="Sec2"><title>Review</title><sec id="Sec3"><title>Hypertrophic scars</title><p>Hypertrophic scars are defined as visible raised scars which do not spread beyond the original injury margins. Hypertrophic scars are characterised by proliferation of the dermal tissue, excessive deposition of fibroblast-derived extracellular matrix (ECM) over a prolonged period of time and persistent inflammation and fibrosis [<xref ref-type="bibr" rid="CR5">5</xref>]. Hypertrophic scars primarily contain collagen type III orientated parallel to the epidermal surface with abundant collagen nodules [<xref ref-type="bibr" rid="CR6">6</xref>]. This structural realignment results in contracture, low tensile strength and raised scars.</p><p>The incidence of hypertrophic scars after a burn remains unclear, with estimates ranging from 26 % to 75&#x000a0;% depending on age, ethnicity and if healing was spontaneous or through surgical means (for example, skin grafting) [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Apart from the aesthetic problems, patients often complain of itching, redness and hard nodular scar tissue often with abnormal sensation. Hypertrophic scars following thermal injury are often associated with contractures, which can result in functional loss especially over joints such as in the hand [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec4"><title>Scar formation</title><p>Wound healing is an inherent process which aims to restore the integrity of the skin as rapidly as possible. Wound healing is divided into four stages: haemostasis, inflammation, proliferation and tissue remodelling. Within these four stages, which often overlap,&#x000a0;there are numerous interactions between fibrotic and anti-fibrotic growth factors, cells, ECM components and numerous enzymes [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Fibroblasts derived from hypertrophic scars have demonstrated an altered phenotype compared to fibroblasts derived from normal scars and fibroblasts derived from uninjured tissue [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Fibroblasts derived from hypertrophic scars have demonstrated both an increased expression of the pro-fibrotic cytokine, transforming growth factor beta 1 (TGF-&#x003b2;1), and a prolonged expression of the associated TGF-&#x003b2; receptors (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Further, there appears to be an alteration in TGF-&#x003b2; signalling (via increased phosphorylation of the receptor Smad proteins) in hypertrophic-derived fibroblasts and a decreased expression of the inhibitory Smad 7 in hypertrophic scar-derived fibroblasts [<xref ref-type="bibr" rid="CR18">18</xref>]. Studies have indicated that ectopic expression of Smad 7 prevents collagen contraction in both normal and hypertrophic scar-derived fibroblasts (FPCL: fibroblast-populated collagen lattice: model for contraction) [<xref ref-type="bibr" rid="CR19">19</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Summary of TGF-&#x003b2; signalling in hypertrophic scars (Reprinted from Penn JW, Grobbelaar AO, Rolfe KJ. The role of TGF-&#x003b2; family in wound healing, burns and scarring: a review. Int J Burns Trauma. 2012;2:18&#x02013;28. With permission). <italic>TGF-&#x003b2;1</italic> transforming growth factor beta 1, <italic>HTS</italic> hypertrophic scar, <italic>LAP</italic> latency-associated peptide, <italic>LTBP</italic> latebt transforming growth factor-beta-1 binding portein, <italic>CTGF</italic> connective tissue growth factor, <italic>TIMP-1</italic>&#x000a0;tissue inhibitor of metalloproteinase-1</p></caption><graphic xlink:href="41038_2016_40_Fig1_HTML" id="MO1"/></fig></p><p>A mouse model which lacked the receptor Smad, Smad 3, showed improved wound healing [<xref ref-type="bibr" rid="CR20">20</xref>]. Conversely, exogenous Smad 3 (via an adenovirus-containing Smad 3 cDNA) in a rabbit dermal ulcer model showed increased granulation tissue and re-epithelisation [<xref ref-type="bibr" rid="CR21">21</xref>]. Sumiyoshi and colleagues suggested that the differences in outcome may be that the adenovirus-containing Smad targeted mainly fibroblasts [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], whereas in the mouse model lacking Smad 3, the deficiency was found in fibroblasts, keratinocytes and inflammatory cells.</p><p>Decorin, a proteoglycan found in the dermal ECM, binds and regulates TGF-&#x003b2;1 and plays a role in collagen fibrillinogenesis. Decorin has been shown to be diminished in hypertrophic scars [<xref ref-type="bibr" rid="CR23">23</xref>]. Zhang and his&#x000a0;colleagues demonstrated that decorin inhibited both basal and TGF-&#x003b2; induced contraction in FPCL in normal and hypertrophic derived fibroblasts [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>Linge et al. demonstrated that fibroblasts derived from hypertrophic scars failed to undergo apoptosis during FPCL contraction unlike fibroblasts derived from normal scars [<xref ref-type="bibr" rid="CR25">25</xref>]. It was determined that the hypertrophic scar-derived fibroblasts were resistant to breakdown by collagenase D and matrix metalloproteinase-2 (MMP-2) due to excessive cross-linking of the FPCL. Linge and colleagues further found that hypertrophic scar-derived fibroblasts over-expressed tissue transglutaminase [<xref ref-type="bibr" rid="CR25">25</xref>]. Reducing tissue transglutaminase in hypertrophic FPCL induced apoptosis on gel contraction [<xref ref-type="bibr" rid="CR25">25</xref>]. Differences have been further identified in myofibroblasts, and these fibroblasts express alpha smooth muscle actin and are associated with wound contraction and maturation of the granulation tissue [<xref ref-type="bibr" rid="CR26">26</xref>]. Myofibroblasts derived from hypertrophic scars appear to be less sensitive to apoptotic signals than fibroblasts derived from normal scars and express different levels of some apoptotic-related molecules [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>Studies suggest that migrating fibrocytes, cells with a distinct cytokine and chemokine profile, may play a role in wound repair and therefore scarring [<xref ref-type="bibr" rid="CR28">28</xref>]. Fibrocytes appear to be increased in number of healing burn wounds and were higher in hypertrophic scar than in mature scar tissue [<xref ref-type="bibr" rid="CR29">29</xref>]. Fibrocytes from patients who have undergone thermal injury appear to differ in their paracrine effects on dermal fibroblasts by stimulating fibroblasts to proliferate, produce and contract the ECM and stimulate production of TGF-&#x003b2;1 and its downstream effector connective tissue growth factor (CTGF/CCN2) [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>Matrix metalloproteinases are involved in the breakdown of the ECM during a number of physiological processes. MMP-1 is involved in the degradation of interstitial collagens, type I, II and III. Hypertrophic-derived fibroblasts appear to have reduced collagenase (MMP-1) activity [<xref ref-type="bibr" rid="CR31">31</xref>]. Though other studies have shown an increase in expression of MMP-2 and low level of MMP-9 [<xref ref-type="bibr" rid="CR32">32</xref>], MMP-2 has been demonstrated to effect matrix remodelling in late wound healing, degrading denatured collagen, whereas MMP-9 appears to be involved in early wound healing degrading collagen types IV and V, fibronectin and elastin [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p><p>Evidence suggests that the immune response may play a role in scarring. Studies have suggested an abnormality in the role of Th1/Th2 paradigm after a thermal injury [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Studies have implicated Toll-like receptors in fibrosis with recent studies implicating increased expression of toll-like receptor 4 (TLR4) mRNA and surface receptors implicating the Toll receptor system in potential activation of dermal fibroblast in hypertrophic scars [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec5"><title>Treatment for scar</title><p>Numerous treatments are used to reduce or prevent scarring [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Identifying injuries, which if permitted to heal spontaneously may&#x000a0;result in pathological scarring, is important to prevent unnecessary treatment as few treatments are without side effects [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Compression therapy (pressure garments) has shown mixed results with a meta-analysis showing no alteration in scar scores [<xref ref-type="bibr" rid="CR41">41</xref>], whereas a 12-year prospective study showed an overall significant improvement in scar appearance [<xref ref-type="bibr" rid="CR42">42</xref>]. The mechanism for pressure in the reduction of scarring remains unclear though in vitro studies suggest a change in MMP, collagen and alpha smooth muscle actin expression [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Patient compliance is often low due to discomfort which may affect the overall clinical result, but further compression therapy has well-recognised complications [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p><p>Silicone gel is commonly used in the treatment or prevention of pathological scars. Results for the use of silicone gel either on its own or with compression garments remain conflicting [<xref ref-type="bibr" rid="CR47">47</xref>], but this may in part be due to patient compliance [<xref ref-type="bibr" rid="CR48">48</xref>]. The mechanism of action for silicone gel remains unclear though a recent study suggests that silicone gel alters the expression of TGF-&#x003b2;1, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) 4&#x000a0;months after surgery for surgical scar revision though patient numbers were small (<italic>n</italic>&#x02009;=&#x02009;4) and the original injuries were not discussed [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p>Intra-lesional corticosteroids have shown to be useful in vivo through a number of mechanisms including reduction in the inflammatory process, decrease in collagen production and fibroblast proliferation [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Scar response rates for triamcinolone acetonide (10 to 40&#x000a0;mg/ml), the most common corticosteroid used for scar reduction, range from 50 % to 100&#x000a0;% with a recurrence rate of 9 %&#x02013;53&#x000a0;% (reviewed in [<xref ref-type="bibr" rid="CR50">50</xref>]). However, the use of corticosteroids is often associated with pain on injection and up to 50&#x000a0;% of patients report side effects [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p>Other treatments which are currently being studied include laser therapy [<xref ref-type="bibr" rid="CR53">53</xref>], bleomycin, interferon, 5-fluorouracil, imiquimod, methotrexate and cryotherapy [<xref ref-type="bibr" rid="CR54">54</xref>]. However, to date, there is no effective &#x02018;gold standard&#x02019; for the treatment or prevention of any scarring.</p></sec><sec id="Sec6"><title>Plant-based products</title><p>A number of plants with medical properties have been studied for their effectiveness in the prevention of scarring [<xref ref-type="bibr" rid="CR55">55</xref>]. The present review provides in vitro and/or in vivo evidence supporting plant-based products as potential therapeutic agents.</p><sec id="Sec7"><title>Quercetin</title><p>Quercetin is a flavonoid found in plants, vegetables and fruits including onions, apples and berries [<xref ref-type="bibr" rid="CR56">56</xref>]. Quercetin has been demonstrated in vitro to have a number of biological properties including tumour suppression and anti-inflammatory, anti-oxidant properties and is anti-bacterial [<xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. However, the metabolism of quercetin in humans may reduce its biological effects [<xref ref-type="bibr" rid="CR61">61</xref>].</p><p>Quercetin has been shown in vitro to reduce proliferation in fibroblasts derived from keloid scars and alter intracellular signalling pathways and collagen synthesis [<xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>]. Phan and colleagues demonstrated that in fibroblasts derived from keloid and hypertrophic scars, quercetin not only inhibited fibroblast proliferation by inducing cell cycle arrest but also inhibited FPCL contraction, though both cell cycle arrest and FPCL could be reversed and though resumption of contraction was slowest in the quercetin treated group [<xref ref-type="bibr" rid="CR65">65</xref>]. Saulis and colleagues showed in a rabbit model that Mederma (active compound allium cepa, a derivative of quercetin) improved collagen organisation and therefore may have an effect on the pathophysiology of hypertrophic scars [<xref ref-type="bibr" rid="CR66">66</xref>].</p></sec><sec id="Sec8"><title>Onion extract</title><p>Onion extract in in vitro studies suggest that it may have anti-inflammatory and anti-proliferative properties on fibroblasts and mast cells and increase the expression of MMP-1 [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Quercetin and onion extract have both been shown to induce the up-regulation of MMP-1 in vitro and in vivo [<xref ref-type="bibr" rid="CR68">68</xref>]. MMP-1 is known to play a role in ECM remodelling and therefore quercetin and onion extract may play a role in anti-fibrotic processes.</p><p>A small (<italic>n</italic>&#x02009;=&#x02009;16) randomised controlled split scar study on Asian women undergoing a Pfannenstiel&#x02019;s incision for caesarean section demonstrated a statistically significant reduction in scar height and symptoms at 4 and 12&#x000a0;weeks post-surgery in an onion extract group. However, there was no statistically significant reduction in redness or pliability of the scar over the time studied [<xref ref-type="bibr" rid="CR69">69</xref>]. Ho et al. using a gel containing onion extract, heparin and allotonin found the gel significantly reduced the risk of scarring in 120 Chinese patients undergoing laser removal of their tattoos [<xref ref-type="bibr" rid="CR70">70</xref>]. Wananukul et al., in a paediatric group (<italic>n</italic>&#x02009;=&#x02009;39; mean age 4.3&#x000a0;years&#x000a0;old) who underwent a median sternotomy in a split scar experimental study (onion extract versus placebo), demonstrated that onion extract in a silicone derivative gel significantly decreased the incidence of hypertrophic scars, whereas there was no significant difference in the incidence of keloid scars [<xref ref-type="bibr" rid="CR71">71</xref>]. Other authors have used a combination of a silicone derivative plus onion extract in patients who had undergone a median sternotomy (<italic>n</italic>&#x02009;=&#x02009;60) over a treatment period of 12&#x000a0;weeks. They found that itch and pain was less for the treated group, there was also an improved Vancouver Scar score in the treated group especially for pigmentation [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p>Beuth and colleagues compared hypertrophic scars treated with Contractubex&#x000ae; (cepae extract, heparin, allantoin; treatment group) for 28&#x000a0;days with one intra-lesional corticosteroid application (control group) [<xref ref-type="bibr" rid="CR73">73</xref>]. Contractubex&#x000ae; demonstrated a significant shorter time for normalisation of the scar (erythema, pruritus and consistency) compared to the corticosteroid group. Contractubex&#x000ae; was further associated with less adverse events than corticosteroid application [<xref ref-type="bibr" rid="CR73">73</xref>].</p></sec><sec id="Sec9"><title>Resveratrol</title><p>Resveratrol is a natural plant polyphenol and phyto-oestrogen, present in grape skin, red wine, and peanuts [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Resveratrol is noted to have a number of beneficial health effects including cardio-vascular, anti-inflammatory and anti-oxidant properties [<xref ref-type="bibr" rid="CR74">74</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref>].</p><p>Resveratrol has been shown to reduce fibroblast cell proliferation through cell cycle arrest at G1 in fibroblasts derived from hypertrophic scars and normal skin fibroblasts and induce apoptosis [<xref ref-type="bibr" rid="CR79">79</xref>]. Resveratrol further decreased hydroxyproline levels and down-regulated the expression of collagen type I and III mRNA [<xref ref-type="bibr" rid="CR79">79</xref>].</p><p>Resveratrol has further shown beneficial effects in preventing surgical adhesions in an animal model [<xref ref-type="bibr" rid="CR80">80</xref>]. Ikeda et al. demonstrated in vitro that resveratrol decreases TGF-&#x003b2;1, type 1 collagen and alpha smooth muscle actin in keloid-derived fibroblasts [<xref ref-type="bibr" rid="CR81">81</xref>]. Further, resveratrol suppressed keloid-derived fibroblast proliferation and induced apoptosis. Interestingly, resveratrol did not have the same effects on alpha smooth muscle actin or type 1 collagen in fibroblasts derived from normal scars [<xref ref-type="bibr" rid="CR81">81</xref>].</p></sec><sec id="Sec10"><title>Epigallocatechin gallate (EGCG)</title><p>EGCG is a major catechin in green tea and has a number of biological properties; it has been shown to potentially play a role in preventing fibrosis in a number of organs [<xref ref-type="bibr" rid="CR82">82</xref>].</p><p>EGCG has been shown in FPCL to abrogate contraction stimulated by PDGF and TGF-&#x003b2;1 [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. EGCG binds directly to PDGF-BB preventing the PDGF ligand binding to its receptor and therefore preventing both proliferation and FPCL contraction [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. EGCG has been shown to inhibit a number of intracellular signalling pathways and reduce expression of pro-fibrotic molecules (vascular endothelial growth factor (VEGF), TGF-&#x003b2;1, CTGF) in a number of organs [<xref ref-type="bibr" rid="CR86">86</xref>&#x02013;<xref ref-type="bibr" rid="CR88">88</xref>]. Inhibition of TGF-&#x003b2;1 results in reduction of the synthesis of the ECM [<xref ref-type="bibr" rid="CR84">84</xref>]. Interestingly, EGCG has been demonstrated to improve re-epithelisation in a chronic wound model and the structural stability of collagen was shown to be enhanced with EGCG [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>].</p></sec><sec id="Sec11"><title>Oleanolic acid&#x000a0;(OA)</title><p>OA is a naturally occurring triterpenoid compound with a number of biological properties including anti-inflammatory and anti-tumour effects [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. In a rabbit ear model of hypertrophic scarring where OA was applied daily for 22&#x000a0;days, it was found to significantly inhibit hypertrophic scarring with a corresponding reduction in TGF-&#x003b2;1 and collagen type I and III and increase levels of MMP-1 [<xref ref-type="bibr" rid="CR93">93</xref>]. Zhang et al. also used the rabbit ear model to study OA and repeated the observation that OA reduced the incidence of hypertrophic type scars [<xref ref-type="bibr" rid="CR94">94</xref>]. They found that TGF-&#x003b2;1, MMP-1, TIMP-1 and collagen I and III were notably decreased though the number of apoptotic cells and mRNA expression of MMP-2, caspase-3 and caspase-9 were increased in the scar tissue [<xref ref-type="bibr" rid="CR94">94</xref>].</p></sec><sec id="Sec12"><title>Curcumin</title><p>Curcumin, a polyphenol, has been shown to induce apoptosis in a number of cell lines [<xref ref-type="bibr" rid="CR95">95</xref>&#x02013;<xref ref-type="bibr" rid="CR97">97</xref>]. Curcumin has been shown in a rat wound healing model to increase contraction and reduce wound healing time [<xref ref-type="bibr" rid="CR98">98</xref>]. The wounds showed increased fibronectin and collagen expression with increased collagen maturation and cross-linking increasing the wounds tensile strength after treating with curcumin for 12&#x000a0;days (200&#x000a0;&#x003bc;l at a concentration of 40&#x000a0;mg/kg body weight) [<xref ref-type="bibr" rid="CR98">98</xref>].</p><p>Scharstuhl and colleagues showed that curcumin treatment (&#x0003e;25&#x000a0;&#x003bc;M for 48&#x000a0;h) induced fibroblast apoptosis and inhibited FPCL contraction via a reactive oxygen species (ROS)-mediated process in human dermal fibroblasts in vitro [<xref ref-type="bibr" rid="CR99">99</xref>]. They concluded that curcumin at high concentrations may be a therapeutic strategy in the reduction or prevention of hypertrophic scarring and that the process can be regulated through the modulation of heme oxygenase(HO) molecule activity or the administration of HO effector molecules.</p></sec><sec id="Sec13"><title>Shikonin</title><p>Shikonin is a natural naphthoquinone compound from the Chinese herb <italic>Lithospermum erythrorhizon</italic>. Shikonin has been demonstrated to have a number of molecular targets, inducing apoptosis, necrosis and necroptosis in cancer cells [<xref ref-type="bibr" rid="CR100">100</xref>&#x02013;<xref ref-type="bibr" rid="CR102">102</xref>]. It has further been demonstrated that shikonin selectively kills cancer cells while maintaining normal cells [<xref ref-type="bibr" rid="CR103">103</xref>]. Shikonin in cancer lines has been shown to alter a number of intracellular signalling pathways particularly those associated with apoptosis [<xref ref-type="bibr" rid="CR103">103</xref>&#x02013;<xref ref-type="bibr" rid="CR105">105</xref>]. Fan and colleagues demonstrated that Shikonin keratinocytes did not respond to Shikonin unlike human scar-derived fibroblasts which where stimulated to undergo apoptosis [<xref ref-type="bibr" rid="CR106">106</xref>]. Shikonin induced apoptosis by altering the expression of capsase-3, B-cell lymphoma (BCL)-2, phosphorylation of ERK1/2 and p38 [<xref ref-type="bibr" rid="CR107">107</xref>]. Further, Shikonin down-regulates collagen (type I and III) and smooth muscle actin gene expression in scar-derived fibroblasts [<xref ref-type="bibr" rid="CR107">107</xref>].</p><p>Normal skin fibroblasts (<italic>n</italic>&#x02009;=&#x02009;3) were demonstrated to reduce TGF-&#x003b2;1 induced collagen production when cultured with Shikonin. This was demonstrated to be through alteration of the TGF-&#x003b2;1-SMAD intracellular signalling pathway [<xref ref-type="bibr" rid="CR108">108</xref>]. This pathway further prevented FPCL by down-regulating alpha smooth muscle actin [<xref ref-type="bibr" rid="CR108">108</xref>].</p></sec><sec id="Sec14"><title>Emodin</title><p>Emodin is a resin derived from the Himalayan rhubarb, buckthorn and Japanese knotweed. It has been investigated for a number of therapeutic effects including asthma, arthritis and Alzheimer&#x02019;s disease in a number of animal models [<xref ref-type="bibr" rid="CR109">109</xref>&#x02013;<xref ref-type="bibr" rid="CR112">112</xref>]. Emodin has been shown to alter a number of intracellular signalling pathways including nuclear factor-&#x003ba;B and phosphoinositide 3 kinase/Akt [<xref ref-type="bibr" rid="CR113">113</xref>], which plays a role in a number of cellular processes including the cell cycle. In vitro and in vivo studies have suggested that emodin may potentially play a role in preventing fibrosis in a number of organs [<xref ref-type="bibr" rid="CR113">113</xref>&#x02013;<xref ref-type="bibr" rid="CR116">116</xref>].</p><p>Hypertrophic scars were developed through mechanical stress in an animal model, and emodin was administered intra peritoneally (10&#x000a0;mg/kg). Liu demonstrated that the emodin-treated hypertrophic scar group had an improved histopathological appearance compared to the control group; however, on removal of emodin at day 14, histopathology of the scar was only minimally improved at day 28 [<xref ref-type="bibr" rid="CR113">113</xref>]. Emodin further inhibited the inflammatory response in the hypertrophic scars (tumor necrosis factor (TNF)-&#x003b1; monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6). Emodin was shown to reduce the activation of PI3K and Akt in the hypertrophic fibroblasts, but this was not reciprocated in normal fibroblasts [<xref ref-type="bibr" rid="CR113">113</xref>].</p></sec></sec><sec id="Sec15"><title>Non-plant-based therapeutics</title><sec id="Sec16"><title>Honey</title><p>Honey has been shown to have anti-bacterial properties through the presence of inhibines which consist of hydrogen peroxide, flavonoids, phenolic acids and other as yet unidentified substances [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. Other non-peroxide anti-microbial factors have been identified in honey depending on the floral sources, origin and processing [<xref ref-type="bibr" rid="CR119">119</xref>&#x02013;<xref ref-type="bibr" rid="CR123">123</xref>]. However, studies have implicated that it is not simply its anti-microbial properties that confer its effectiveness in treating wounds [<xref ref-type="bibr" rid="CR124">124</xref>]. Honey activates various components of the immune system in vitro and in vivo which not only activates the immune response but also tissue repair [<xref ref-type="bibr" rid="CR125">125</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref>].</p><p>To date, there have been mixed results with the use of honey on wounds. Nakajima and colleagues using a mouse model and three forms of Japanese honey found that the use of honey had little benefit in wound healing [<xref ref-type="bibr" rid="CR130">130</xref>]. Gupta and colleagues retrospectively compared the hospital records of burns patients who had been treated with either honey dressings or silver sulfadiazine dressings over a period of 5&#x000a0;years [<xref ref-type="bibr" rid="CR131">131</xref>]. They found that honey enhanced healing, reduced contractures and had better overall outcome compared to silver sulfadazine [<xref ref-type="bibr" rid="CR131">131</xref>]. Others have confirmed the beneficial effects of honey and healing time when compared to other dressings including silver sulfadazine-, film- and gauze-based dressings [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR133">133</xref>]. However, silver sulfadiazine has been shown to delay healing and increase pain and infection rates and may therefore have not been the best comparator [<xref ref-type="bibr" rid="CR134">134</xref>]. Honey&#x02019;s anti-inflammatory effect is proposed as the reason why honey reduces fibrosis and scarring [<xref ref-type="bibr" rid="CR135">135</xref>&#x02013;<xref ref-type="bibr" rid="CR137">137</xref>].</p></sec></sec><sec id="Sec17"><title>Adverse events, bioavailability interactions and synergistic effects</title><p>Though considered &#x02018;natural&#x02019;, most of the products are synthetically manufactured; further, even some &#x02018;natural&#x02019; products have been identified as causing toxicities (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>]. There have been limited toxicity studies conducted on the natural therapeutics discussed in this review, though those used in human studies appear to have mild adverse events recorded (such as honey, onion extract, quercetin; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Though there have been individuals who appear to have increased adverse events, resveratrol saw one individual in a study show grade 4 elevation of their liver function markers after 3&#x000a0;months treatment of 1&#x000a0;g of resveratrol daily [<xref ref-type="bibr" rid="CR140">140</xref>]. The patient&#x02019;s markers returned to normal after discontinuing the medication. EGCG has also shown in some individuals to elevate liver function tests though one study concluded it was an issue with the lot [<xref ref-type="bibr" rid="CR141">141</xref>], though a case study did identify drug-induced hepatitis with the use of a concentrated green tea extract [<xref ref-type="bibr" rid="CR142">142</xref>]. Oleanolic acid in animal studies suggests that repeated oral administration can cause liver injury [<xref ref-type="bibr" rid="CR138">138</xref>]. Oleanolic acid derivatives have been also shown to be related to fluid overload which in some individuals resulted in heart failure in patients with stage 4 chronic renal disease (8.8&#x000a0;% of the treated group compared to 5&#x000a0;% of the placebo group) [<xref ref-type="bibr" rid="CR139">139</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Natural therapeutics, where they originate from, their potential mechanism of action and known adverse events, bioavailability and drug interactions</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Natural therapeutic agent</th><th>Origin</th><th>Mechanism of action(s)</th><th>Administered</th><th>Known adverse effects or potential issue with use</th></tr></thead><tbody><tr><td>Quercetin</td><td>Flavonoid found in plants, vegetables and fruits</td><td>&#x02022; Blocks TGF-&#x003b2; (inhibits receptor expression and SMAD2/3 nuclear translocation)&#x02014;in turn alters collagen expression [<xref ref-type="bibr" rid="CR62">62</xref>]<break/>&#x02022; Alters IGF-1 signalling (through reduction in receptor and intracellular signalling)&#x02014;in turn affects keloid fibroblast proliferation [<xref ref-type="bibr" rid="CR63">63</xref>]<break/>&#x02022; Reduces collagen contraction [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td>&#x02022; In vitro [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]</td><td>&#x02022; Bioavailability is problematic though studies have suggested potential ways to improve its availability [<xref ref-type="bibr" rid="CR152">152</xref>]<break/>&#x02022; Adverse events appear mild [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR154">154</xref>]<break/>&#x02022; Interacts with some drugs, e.g. fluoroquinolones, taxol/paciltaxel [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]</td></tr><tr><td>Onion extract (kaempferol, Mederma&#x000ae;, Contractubex&#x000ae;, Cybele&#x000ae;, Eras&#x000e9; gel, Kaloidon gel)</td><td>Onion</td><td>&#x02022; Up-regulates MMP-1 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td>&#x02022; In vitro (human skin fibroblasts) [<xref ref-type="bibr" rid="CR68">68</xref>]<break/>&#x02022; In vivo (hairless mice administered with ointment) [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td>&#x02022; No adverse events [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]<break/>&#x02022; Moderate pruritus, all other adverse events less than the use of corticosteroids [<xref ref-type="bibr" rid="CR73">73</xref>]</td></tr><tr><td>Resveratrol</td><td>Grape skin, red wine and peanuts</td><td>&#x02022; Inhibits fibroblast cell growth, causes cell cycle arrest and induces apoptosis which result in reduced collagen expression [<xref ref-type="bibr" rid="CR79">79</xref>]<break/>&#x02022; Reduced TGF-&#x003b2;1 protein in keloid fibroblasts (<italic>n</italic>&#x02009;=&#x02009;5), reduced cell proliferation and induced apoptosis but did not decrease collagen type I, alpha smooth muscle actin or heat shock protein 47 in normal skin fibroblasts (<italic>n</italic>&#x02009;=&#x02009;1) [<xref ref-type="bibr" rid="CR81">81</xref>]</td><td>&#x02022; In vitro (hypertrophic-derived fibroblasts, normal skin fibroblasts) [<xref ref-type="bibr" rid="CR79">79</xref>]<break/>&#x02022; In vitro (keloid fibroblasts) [<xref ref-type="bibr" rid="CR81">81</xref>]</td><td>&#x02022; In vitro appears to have no genotoxic activity [<xref ref-type="bibr" rid="CR155">155</xref>]<break/>&#x02022; Resveratrol (administered orally) in a number of studies in humans both symptomatic (e.g. Alzheimer&#x02019;s patients, obese patients) and healthy showed minor adverse events, the most common being nausea, weight loss, diarrhoea and skin rash [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR157">157</xref>]<break/>&#x02022; One individual showed elevated hepatic ALT and AST (grade 4) which returned to normal after stopping the medication [<xref ref-type="bibr" rid="CR140">140</xref>]<break/>&#x02022; Boocock et al. [<xref ref-type="bibr" rid="CR149">149</xref>] suggested oral administration may not be sufficient for some therapeutic roles of resveratrol</td></tr><tr><td>Epigallocatechin gallate</td><td>Green tea</td><td>&#x02022; Prevents PDGF-BB binding to its receptor and leads to prevention of proliferation and collagen gel contraction [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]<break/>&#x02022; Known to inhibit a number of intracellular signalling pathways and thereby reducing pro-fibrotic gene expression [<xref ref-type="bibr" rid="CR86">86</xref>&#x02013;<xref ref-type="bibr" rid="CR88">88</xref>] and ECM production [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td>&#x02022; In vitro (neonatal fibroblasts) [<xref ref-type="bibr" rid="CR83">83</xref>]<break/>&#x02022; In vitro (human/rat vascular smooth muscle cells) [<xref ref-type="bibr" rid="CR85">85</xref>]<break/>&#x02022; In vitro (post-natal human dermal fibroblasts [<xref ref-type="bibr" rid="CR84">84</xref>]<break/>&#x02022; In vitro (rat cardiac fibroblasts) [<xref ref-type="bibr" rid="CR86">86</xref>]<break/>&#x02022; In vitro (human gingival fibroblasts) [<xref ref-type="bibr" rid="CR87">87</xref>]<break/>&#x02022; In vitro (human umbilical vein endothelial cells) [<xref ref-type="bibr" rid="CR88">88</xref>]</td><td>&#x02022; EGCG appears well tolerated with oral administration [<xref ref-type="bibr" rid="CR158">158</xref>&#x02013;<xref ref-type="bibr" rid="CR160">160</xref>] or used on the skin [<xref ref-type="bibr" rid="CR161">161</xref>]<break/>&#x02022; Adverse events include mild gastrointestinal issues and skin rashes [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]<break/>&#x02022; Polyphenon E has been linked to elevated liver function tests but this appeared related to the LOT [<xref ref-type="bibr" rid="CR141">141</xref>] though a case study showed a case of drug-induced hepatitis [<xref ref-type="bibr" rid="CR142">142</xref>] and other studies have shown minor increase in liver markers [<xref ref-type="bibr" rid="CR162">162</xref>]<break/>&#x02022; Number of chemotherapy agents [<xref ref-type="bibr" rid="CR146">146</xref>]</td></tr><tr><td>Oleanolic acid</td><td>Number of foods, for example, olive oil, garlic, etc</td><td>&#x02022; Decreased TGF-&#x003b2;1 and collagen I and III and increased MMP-1 [<xref ref-type="bibr" rid="CR93">93</xref>] possibly through decreased fibroblast proliferation, increased apoptosis and degradation of collagen types I and III through enhanced MMP-2 activity [<xref ref-type="bibr" rid="CR94">94</xref>]</td><td>&#x02022; In vivo (rabbit ear model for hypertrophic scars; applied as an ointment) [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]</td><td>&#x02022; Animal model associated with male infertility [<xref ref-type="bibr" rid="CR163">163</xref>]<break/>&#x02022; Oral administration in an animal model (dose, 22.5&#x02013;135&#x000a0;mg/kg) for 5&#x000a0;days. Liver injury observed at doses of 90&#x000a0;mg/kg and above [<xref ref-type="bibr" rid="CR138">138</xref>]<break/>&#x02022; Bardoxolone methyl&#x02014;semi-synthetic triterpenoid based on the scaffold of oleanolic acid&#x02014;caused heart failure in patients with stage 4 chronic kidney disease [<xref ref-type="bibr" rid="CR139">139</xref>]</td></tr><tr><td>Curcumin</td><td>Rhizome of <italic>Curcuma longa</italic> and related species.</td><td>&#x02022; Induced fibroblast apoptosis and reduced collagen gel contraction [<xref ref-type="bibr" rid="CR99">99</xref>] via ROS mechanism</td><td>&#x02022; In vitro (human fibroblasts) [<xref ref-type="bibr" rid="CR99">99</xref>]</td><td>&#x02022; Poor bioavailability especially after oral administration [<xref ref-type="bibr" rid="CR164">164</xref>]<break/>&#x02022; Appears well tolerated up to 8&#x000a0;g/day up to 3&#x000a0;months [<xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR165">165</xref>]<break/>&#x02022; Adverse effects may change with adaptations that are used to improve bioavailability<break/>&#x02022; Chelate iron suppresses hepcidin therefore potentially causing iron deficiency [<xref ref-type="bibr" rid="CR166">166</xref>]<break/>&#x02022; Interacts with 5-fluorouracil and vinorelbine [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]</td></tr><tr><td>Shikonin</td><td>Chinese herb<break/>Radix Arnebiae</td><td>&#x02022; Induces apoptosis in fibroblasts [<xref ref-type="bibr" rid="CR106">106</xref>]<break/>&#x02022; Down-regulates collagen types I and III and &#x003b1; smooth muscle actin [<xref ref-type="bibr" rid="CR107">107</xref>]<break/>&#x02022; Appears to induce apoptosis by altering p-ERK 1/2, p-p38 and caspase-3 [<xref ref-type="bibr" rid="CR107">107</xref>]</td><td>&#x02022; In vitro (human keratinocytes, skin fibroblasts) [<xref ref-type="bibr" rid="CR106">106</xref>]<break/>&#x02022; In vitro (human keratinocytes, human skin fibroblasts, hypertrophic scar-derived fibroblasts) [<xref ref-type="bibr" rid="CR107">107</xref>]</td><td>&#x02022; Low bioavailability due to high lipophilicity [<xref ref-type="bibr" rid="CR167">167</xref>] altered through the formation of a complex with other proteins [<xref ref-type="bibr" rid="CR150">150</xref>]<break/>&#x02022; Limited toxicity studies&#x02014;one animal study demonstrated that it appeared safe up to concentrations of 800&#x000a0;mg/kg for 180&#x000a0;days [<xref ref-type="bibr" rid="CR168">168</xref>]</td></tr><tr><td>Emodin</td><td>Derived from the Himalayan rhubarb, buckthorn and Japanese knotweed</td><td>&#x02022; Alters the intracellular pathway of Pi3K and Akt but only in hypertrophic scar-derived fibroblasts [<xref ref-type="bibr" rid="CR113">113</xref>] and this in turn inhibited the inflammatory response and improved the histopathology appearance of the scar [<xref ref-type="bibr" rid="CR113">113</xref>]</td><td>&#x02022; In vivo and in vitro (mice model for hypertrophic scars, emodin was administered intra-peritoneally; mice derived hypertrophic scarring fibroblasts and normal fibroblasts) [<xref ref-type="bibr" rid="CR113">113</xref>]</td><td>&#x02022; Not known as yet</td></tr><tr><td>Honey</td><td/><td>&#x02022; Accelerates wound healing due to its anti- bacterial activity, anti-oxidant activity, stimulator effects and anti-inflammatory effects [<xref ref-type="bibr" rid="CR135">135</xref>&#x02013;<xref ref-type="bibr" rid="CR137">137</xref>]</td><td>&#x02022; Human patients with burns&#x02014;honey-impregnated gauze [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>]</td><td>&#x02022; Stinging pain on administration, local atopic reactions in paediatric group [<xref ref-type="bibr" rid="CR169">169</xref>]</td></tr></tbody></table><table-wrap-foot><p>
<italic>TGF-&#x003b2;1</italic>&#x000a0;transforming growth factor beta 1, <italic>IGF-1</italic> insulinlike growth factor-1, <italic>MMP</italic>&#x000a0;matrix metalloproteinase, <italic>PDGF-BB</italic> platelet-derived growth factor-BB, <italic>ECM</italic>&#x000a0;extracellular matrix, <italic>RGCG</italic> epigallocatechin gallate, <italic>ROS</italic> reactive oxygen species</p></table-wrap-foot></table-wrap></p><p>It has been well recognised that some herbal products can interact with medicinal drugs and reduce or prevent their effectiveness, e.g. St John&#x02019;s wort (<italic>Hypericum perforatum</italic>), and in some cases, alter the efficacy of medicinal drugs [<xref ref-type="bibr" rid="CR143">143</xref>]. A number of the products discussed in this paper have also been shown to interact with other drugs including antibiotics (fluoroquinones) and chemotherapy agents [<xref ref-type="bibr" rid="CR144">144</xref>&#x02013;<xref ref-type="bibr" rid="CR148">148</xref>].</p><p>A number of the agents have been shown to have low bioavailability (quercetin, curcumin, shikonin), and others have been suggested that oral administration may not be sufficient for therapeutic levels to be reached or indeed maintained [<xref ref-type="bibr" rid="CR149">149</xref>]. Further, those that have low bioavailability which are then either manipulated or other proteins added this structural alteration may affect both adverse events and the actual therapeutic mechanisms [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>]. To date, there remains a paucity of information in regard to the safety of some of these agents in their use as anti-scarring products.</p></sec></sec><sec id="Sec18" sec-type="conclusion"><title>Conclusions</title><p>In vitro and in vivo studies have shown that a number of &#x02018;natural&#x02019; therapeutic agent and strategies may play a role in the future treatment of scarring, particularly hypertrophic scarring which is so intrinsically linked with burn injuries. There remains no gold standard in the treatment or prevention of scarring. It remains problematic comparing all products not just natural therapeutics in part due to the number of methodologies used to assess the effectiveness of anti-scarring therapeutics and the number of models used. Further, those that do undergo clinical trials, the variation in patients and outcome measures is immense leading to problems in comparing agents and is often undertaken once the scar has formed. There is a theoretical risk which agents that reduce or prevent scarring may in turn prevent or lengthen the wound healing process, and this has yet to be elucidated. However, it appears that there is a potential for a natural therapeutic as either a monotherapy or as an adjunct to play a role in treating or even preventing hypertrophic scarring.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ECM</term><def><p>extracellular matrix</p></def></def-item><def-item><term>FPCL</term><def><p>fibroblast-populated collagen lattice</p></def></def-item><def-item><term>MMP</term><def><p>matrix metalloproteinase</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>KR conceived the idea and drafted the manuscript. MM and OB participated in the design and coordination. All authors read and approved the final manuscript.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs365/en/">http://www.who.int/mediacentre/factsheets/fs365/en/</ext-link> Accessed 5th Jan 2016</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">American Burn Association. <ext-link ext-link-type="uri" xlink:href="http://ameriburn.org/resources_factsheet.php">http://ameriburn.org/resources_factsheet.php</ext-link> accessed 9th Jul 2015</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">WHO <ext-link ext-link-type="uri" xlink:href="http://www.who.int/violence_injury_prevention/other_injury/burns/en/">http://www.who.int/violence_injury_prevention/other_injury/burns/en/</ext-link> Accessed 9th Jul 2015</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheridan</surname><given-names>RL</given-names></name></person-group><article-title>Burn care: results of technical and organizational progress</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>719</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1001/jama.290.6.719</pub-id><pub-id pub-id-type="pmid">12915409</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>AJ</given-names></name><name><surname>Clark</surname><given-names>RA</given-names></name></person-group><article-title>Cutaneous wound healing</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>738</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1056/NEJM199909023411006</pub-id><pub-id pub-id-type="pmid">10471461</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauglitz</surname><given-names>GG</given-names></name><name><surname>Korting</surname><given-names>HC</given-names></name><name><surname>Pavicic</surname><given-names>T</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>Jeschke</surname><given-names>MG</given-names></name></person-group><article-title>Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies</article-title><source>Mol Med</source><year>2011</year><volume>17</volume><issue>1&#x02013;2</issue><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">20927486</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deitch</surname><given-names>EA</given-names></name><name><surname>Wheelahan</surname><given-names>TM</given-names></name><name><surname>Rose</surname><given-names>MP</given-names></name><name><surname>Clothier</surname><given-names>J</given-names></name><name><surname>Cotter</surname><given-names>J</given-names></name></person-group><article-title>Hypertrophic burn scars: analysis of variables</article-title><source>J Trauma</source><year>1983</year><volume>23</volume><fpage>895</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1097/00005373-198310000-00009</pub-id><pub-id pub-id-type="pmid">6632013</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>WS</given-names></name><name><surname>Deitch</surname><given-names>EA</given-names></name></person-group><article-title>Hypertrophic skin grafts in burned patients: a prospective analysis of variables</article-title><source>J Trauma</source><year>1987</year><volume>27</volume><fpage>147</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1097/00005373-198702000-00008</pub-id><pub-id pub-id-type="pmid">3546710</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spurr</surname><given-names>ED</given-names></name><name><surname>Shakespeare</surname><given-names>PG</given-names></name></person-group><article-title>Incidence of hypertrophic scarring in burn-injured children</article-title><source>Burns</source><year>1990</year><volume>16</volume><fpage>179</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/0305-4179(90)90034-T</pub-id><pub-id pub-id-type="pmid">2383356</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dedovic</surname><given-names>Z</given-names></name><name><surname>Koupilova</surname><given-names>I</given-names></name><name><surname>Brychta</surname><given-names>P</given-names></name></person-group><article-title>Time trends in incidence of hypertrophic scarring in children treated for burns</article-title><source>Acta Chir Plast</source><year>1999</year><volume>41</volume><issue>3</issue><fpage>87</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">10641329</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bombaro</surname><given-names>KM</given-names></name><name><surname>Engrav</surname><given-names>LH</given-names></name><name><surname>Carrougher</surname><given-names>GJ</given-names></name><name><surname>Wiechman</surname><given-names>SA</given-names></name><name><surname>Faucher</surname><given-names>L</given-names></name><name><surname>Costa</surname><given-names>BA</given-names></name><etal/></person-group><article-title>What is the prevalence of hypertrophic scarring following burns?</article-title><source>Burns</source><year>2003</year><volume>9</volume><fpage>299</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/S0305-4179(03)00067-6</pub-id><pub-id pub-id-type="pmid">12781605</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangemi</surname><given-names>EN</given-names></name><name><surname>Gregori</surname><given-names>D</given-names></name><name><surname>Berchialla</surname><given-names>P</given-names></name><name><surname>Zingarelli</surname><given-names>E</given-names></name><name><surname>Cairo</surname><given-names>M</given-names></name><name><surname>Bollero</surname><given-names>D</given-names></name><etal/></person-group><article-title>Epidemiology and the risk factors for pathological scarring after burn wounds</article-title><source>Arch Facial Plast Surg</source><year>2008</year><volume>10</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1001/archfaci.10.2.93</pub-id><pub-id pub-id-type="pmid">18347236</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>JC</given-names></name><name><surname>Holvanahalli</surname><given-names>R</given-names></name><name><surname>Helm</surname><given-names>P</given-names></name><name><surname>Goldstein</surname><given-names>R</given-names></name><name><surname>Kowalske</surname><given-names>K</given-names></name></person-group><article-title>Contractures in burn injury; defining the problem</article-title><source>J Burn Care Res</source><year>2006</year><volume>27</volume><fpage>508</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1097/01.BCR.0000225994.75744.9D</pub-id><pub-id pub-id-type="pmid">16819356</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tredget</surname><given-names>EE</given-names></name></person-group><article-title>Pathophysiology and treatment of fibroproliferative disorders following thermal injury</article-title><source>Ann N Y Acad Sci</source><year>1999</year><volume>888</volume><fpage>165</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb07955.x</pub-id><pub-id pub-id-type="pmid">10842632</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>SS</given-names></name><name><surname>Hajrah</surname><given-names>NH</given-names></name><name><surname>Ayuob</surname><given-names>NN</given-names></name><name><surname>Moshref</surname><given-names>SS</given-names></name><name><surname>Abuzinadah</surname><given-names>OA</given-names></name></person-group><article-title>Morphological and morphometric study of cultured fibroblast from treated and untreated abnormal scar</article-title><source>Saudi Med J</source><year>2010</year><volume>30</volume><fpage>874</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">20714684</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>P</given-names></name><name><surname>Itin</surname><given-names>P</given-names></name><name><surname>Bi</surname><given-names>C</given-names></name><name><surname>Cox</surname><given-names>DA</given-names></name></person-group><article-title>Enhanced expression of transforming growth factor- beta type I and type II receptors in wound granulation tissue and hypertrophic scar</article-title><source>Am J Pathol</source><year>1998</year><volume>15</volume><issue>2</issue><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">9466575</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Ghahary</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Scott</surname><given-names>PG</given-names></name><name><surname>Roy</surname><given-names>K</given-names></name><name><surname>Tredget</surname><given-names>EE</given-names></name></person-group><article-title>Hypertrophic scar tissues and fibroblasts produce more transforming growth factor- beta 1 mRNA and protein than normal skin and cells</article-title><source>Wound Repair and Regen</source><year>2000</year><volume>8</volume><fpage>128</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1046/j.1524-475x.2000.00128.x</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>JL</given-names></name><name><surname>Qi</surname><given-names>SH</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>YB</given-names></name><name><surname>Li</surname><given-names>TZ</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><etal/></person-group><article-title>Expression of Smad proteins by normal skin fibroblasts and hypertrophic scar fibroblasts in response to transforming growth factor beta 1</article-title><source>Dermatol Surg</source><year>2008</year><volume>34</volume><fpage>1216</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1097/00042728-200809000-00008</pub-id><pub-id pub-id-type="pmid">18616749</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopp</surname><given-names>J</given-names></name><name><surname>Preis</surname><given-names>E</given-names></name><name><surname>Said</surname><given-names>H</given-names></name><name><surname>Hafemann</surname><given-names>B</given-names></name><name><surname>Wickert</surname><given-names>L</given-names></name><name><surname>Gressner</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Abrogation of transforming growth factor-B signalling by SMAD 7 inhibits collagen gel contraction of human dermal fibroblasts</article-title><source>J Biol Chem</source><year>2006</year><volume>22</volume><issue>3</issue><fpage>21570</fpage><lpage>21576</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashcroft</surname><given-names>GS</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Glick</surname><given-names>AB</given-names></name><name><surname>Weinstein</surname><given-names>M</given-names></name><name><surname>Letterio</surname><given-names>JL</given-names></name><name><surname>Mizel</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response</article-title><source>Nat Cell Biol</source><year>1999</year><volume>1</volume><issue>5</issue><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1038/12971</pub-id><pub-id pub-id-type="pmid">10559937</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumiyoshi</surname><given-names>K</given-names></name><name><surname>Nakao</surname><given-names>A</given-names></name><name><surname>Setoguchi</surname><given-names>Y</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name></person-group><article-title>Exogenous Smad3 accelerates wound healing in a rabbit derma ulcer model</article-title><source>J Invest Dermatol</source><year>2004</year><volume>123</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1111/j.0022-202X.2004.22730.x</pub-id><pub-id pub-id-type="pmid">15191565</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setoguchi</surname><given-names>Y</given-names></name><name><surname>Jaffe</surname><given-names>HA</given-names></name><name><surname>Danel</surname><given-names>C</given-names></name><name><surname>Cystal</surname><given-names>RG</given-names></name></person-group><article-title>Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors</article-title><source>J Invest Dermatol</source><year>1994</year><volume>102</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12372181</pub-id><pub-id pub-id-type="pmid">8151119</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>PG</given-names></name><name><surname>Dodd</surname><given-names>CM</given-names></name><name><surname>Tredget</surname><given-names>EE</given-names></name><name><surname>Ghahary</surname><given-names>A</given-names></name><name><surname>Rahemtulla</surname><given-names>F</given-names></name></person-group><article-title>Chemical characterisation and quantification of proteoglycans in human post burn hypertrophic and mature scars</article-title><source>Clin Sci (London)</source><year>1996</year><volume>90</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1042/cs0900417</pub-id><pub-id pub-id-type="pmid">8665780</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Garron</surname><given-names>TM</given-names></name><name><surname>Li</surname><given-names>XJ</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Recombinant human decorin inhibits TGF-beta 1 induced contraction of collagen lattice by hypertrophic scar fibroblasts</article-title><source>Burns</source><year>2009</year><volume>35</volume><issue>4</issue><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.burns.2008.08.021</pub-id><pub-id pub-id-type="pmid">19167828</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linge</surname><given-names>C</given-names></name><name><surname>Richardson</surname><given-names>J</given-names></name><name><surname>Vigor</surname><given-names>C</given-names></name><name><surname>Clayton</surname><given-names>E</given-names></name><name><surname>Hardas</surname><given-names>B</given-names></name><name><surname>Rolfe</surname><given-names>K</given-names></name></person-group><article-title>Hypertrophic scars cells fail to undergo a form of apoptosis specific to contractile collagen- the role of transglutaminase</article-title><source>J Invest Dermatol</source><year>2005</year><volume>12</volume><fpage>72</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23771.x</pub-id><pub-id pub-id-type="pmid">15982305</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>B</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name></person-group><article-title>Cell-matrix and cell-cell contacts of myofibroblasts: role in connective tissue remodeling</article-title><source>Thromb Haemost</source><year>2003</year><volume>90</volume><issue>6</issue><fpage>993</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">14652629</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulin</surname><given-names>V</given-names></name><name><surname>Larochelle</surname><given-names>S</given-names></name><name><surname>Langlois</surname><given-names>C</given-names></name><name><surname>Thibault</surname><given-names>I</given-names></name><name><surname>Lopez-Valle</surname><given-names>CA</given-names></name><name><surname>Roy</surname><given-names>M</given-names></name></person-group><article-title>Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors</article-title><source>J Cell Physiol</source><year>2004</year><volume>198</volume><issue>3</issue><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1002/jcp.10415</pub-id><pub-id pub-id-type="pmid">14755540</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Scott</surname><given-names>PG</given-names></name><name><surname>Giuffre</surname><given-names>J</given-names></name><name><surname>Shankowsky</surname><given-names>HA</given-names></name><name><surname>Ghahary</surname><given-names>A</given-names></name><name><surname>Tredget</surname><given-names>EE</given-names></name></person-group><article-title>Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells</article-title><source>Lab Invest</source><year>2002</year><volume>82</volume><fpage>1183</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1097/01.LAB.0000027841.50269.61</pub-id><pub-id pub-id-type="pmid">12218079</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Scott</surname><given-names>PG</given-names></name><name><surname>Dodd</surname><given-names>C</given-names></name><name><surname>Medina</surname><given-names>A</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Shankowsky</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Identification of fibrocytes in post burn hypertrophic scar</article-title><source>Wound Repair Regen</source><year>2005</year><volume>13</volume><issue>4</issue><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1111/j.1067-1927.2005.130407.x</pub-id><pub-id pub-id-type="pmid">16008729</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Stewart</surname><given-names>TL</given-names></name><name><surname>Shankowsky</surname><given-names>HA</given-names></name><name><surname>Scott</surname><given-names>PG</given-names></name><name><surname>Tredget</surname><given-names>EE</given-names></name></person-group><article-title>Increased TGF-beta-producing CD41 T lymphocytes in post burn patients and their potential interaction with dermal fibro-blasts in hypertrophic scarring</article-title><source>Wound Repair Regen</source><year>2007</year><volume>15</volume><issue>4</issue><fpage>530</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1111/j.1524-475X.2007.00261.x</pub-id><pub-id pub-id-type="pmid">17650097</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eto</surname><given-names>H</given-names></name><name><surname>Suga</surname><given-names>H</given-names></name><name><surname>Aoi</surname><given-names>N</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Doi</surname><given-names>K</given-names></name><name><surname>Kuno</surname><given-names>S</given-names></name><etal/></person-group><article-title>Therapeutic potential of fibroblast growth factor-2 for hypertrophic scars: up regulation of MMP-1 and HGF expression</article-title><source>Lab Invest</source><year>2012</year><volume>92</volume><fpage>214</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2011.127</pub-id><pub-id pub-id-type="pmid">21946856</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neely</surname><given-names>AN</given-names></name><name><surname>Clendening</surname><given-names>CE</given-names></name><name><surname>Gardner</surname><given-names>J</given-names></name><name><surname>Greenhalgh</surname><given-names>DG</given-names></name><name><surname>Warden</surname><given-names>GD</given-names></name></person-group><article-title>Gelatinase activity in keloids and hypertrophic scars</article-title><source>Wound Repair Regen</source><year>1999</year><volume>7</volume><issue>3</issue><fpage>166</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1046/j.1524-475X.1999.00166.x</pub-id><pub-id pub-id-type="pmid">10417752</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauviel</surname><given-names>A</given-names></name></person-group><article-title>Cytokine regulation of metalloproteinase gene expression</article-title><source>J Cell Biochem</source><year>1993</year><volume>53</volume><fpage>288</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1002/jcb.240530404</pub-id><pub-id pub-id-type="pmid">8300745</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>McCluskey</surname><given-names>K</given-names></name><name><surname>Fuji</surname><given-names>K</given-names></name><name><surname>Wahl</surname><given-names>LM</given-names></name></person-group><article-title>Differential regulation of metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte &#x02013;macrophage CSF and IL-1 beta through prostaglandin dependent and independent mechanisms</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>3071</fpage><lpage>3076</lpage><pub-id pub-id-type="pmid">9743373</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tredget</surname><given-names>EE</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Delehanty</surname><given-names>M</given-names></name><name><surname>Shankowsky</surname><given-names>H</given-names></name><name><surname>Scott</surname><given-names>PG</given-names></name></person-group><article-title>Polarized T helper cells Th2 cytokine production in patients with hypertrophic scar following thermal injury</article-title><source>J Interferon Cytokine Res</source><year>2005</year><volume>26</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1089/jir.2006.26.179</pub-id><pub-id pub-id-type="pmid">16542140</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hori</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name><name><surname>Ladak</surname><given-names>A</given-names></name><name><surname>Tredget</surname><given-names>EE</given-names></name></person-group><article-title>Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring</article-title><source>J Cell Physiol</source><year>2011</year><volume>226</volume><issue>5</issue><fpage>1265</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1002/jcp.22454</pub-id><pub-id pub-id-type="pmid">20945369</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liuzzi</surname><given-names>F</given-names></name><name><surname>Chadwick</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>M</given-names></name></person-group><article-title>Paediatric post-burn scar management in the UK: A national survey</article-title><source>Burns</source><year>2015</year><volume>41</volume><issue>2</issue><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.burns.2014.10.017</pub-id><pub-id pub-id-type="pmid">25468478</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidgwick</surname><given-names>GP</given-names></name><name><surname>McGeorge</surname><given-names>D</given-names></name><name><surname>Bayat</surname><given-names>A</given-names></name></person-group><article-title>A comprehensive evidence-based review on the role of topical and dressings in the management of skin scarring</article-title><source>Arch Dermatol Res</source><year>2015</year><volume>307</volume><fpage>461</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1007/s00403-015-1572-0</pub-id><pub-id pub-id-type="pmid">26044054</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>TL</given-names></name><name><surname>Ball</surname><given-names>B</given-names></name><name><surname>Schembri</surname><given-names>PJ</given-names></name><name><surname>Hori</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Shankowsky</surname><given-names>HA</given-names></name><etal/></person-group><article-title>The use of laser Doppler imaging as a predictor of burn depth and hypertrophic scar post burn injury</article-title><source>J Burn Care</source><year>2012</year><volume>33</volume><issue>6</issue><fpage>764</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1097/BCR.0b013e318257db36</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Kwan PO, Ding J, Tredget EE. Serum decorin, IL-1&#x003b2; and TGF-&#x003b2; predict hypertrophic scarring post burn. J Burn care Res. In press.</mixed-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anzarut</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Rowe</surname><given-names>BH</given-names></name><name><surname>Tredget</surname><given-names>EE</given-names></name></person-group><article-title>The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis</article-title><source>J Plast Reconstr Aesthet Surg</source><year>2009</year><volume>62</volume><issue>1</issue><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.bjps.2007.10.052</pub-id><pub-id pub-id-type="pmid">18249046</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engrav</surname><given-names>LH</given-names></name><name><surname>Heimbach</surname><given-names>DM</given-names></name><name><surname>Rivara</surname><given-names>FP</given-names></name><name><surname>Moore</surname><given-names>ML</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Carrougher</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>12-year within-wound study of the effectiveness of custom pressure garment therapy</article-title><source>Burns</source><year>2010</year><volume>36</volume><issue>7</issue><fpage>975</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/j.burns.2010.04.014</pub-id><pub-id pub-id-type="pmid">20537469</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran&#x000f2;</surname><given-names>F</given-names></name><name><surname>Grazianetti</surname><given-names>P</given-names></name><name><surname>Stella</surname><given-names>M</given-names></name><name><surname>Magliacani</surname><given-names>G</given-names></name><name><surname>Pezzulto</surname><given-names>C</given-names></name><name><surname>Cannas</surname><given-names>M</given-names></name></person-group><article-title>Release and activation of matrix metalloproteinase &#x02212;9 during in vitro mechanical compression in hypertrophic scars</article-title><source>Arch Dermatol</source><year>2002</year><volume>138</volume><issue>4</issue><fpage>475</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1001/archderm.138.4.475</pub-id><pub-id pub-id-type="pmid">11939809</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>AM</given-names></name><name><surname>Peyrol</surname><given-names>S</given-names></name><name><surname>P&#x000f4;rto</surname><given-names>LC</given-names></name><name><surname>Comparin</surname><given-names>JP</given-names></name><name><surname>Foyatier</surname><given-names>JL</given-names></name><name><surname>Desmouli&#x000e8;re</surname><given-names>A</given-names></name></person-group><article-title>Mechanical forces induce scar remodelling. Study in non-pressure-treated versus pressure-treated hypertrophic scars</article-title><source>Am J Pathol</source><year>1999</year><volume>155</volume><issue>5</issue><fpage>1671</fpage><lpage>1679</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65482-X</pub-id><pub-id pub-id-type="pmid">10550323</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Greenspan</surname><given-names>B</given-names></name><name><surname>Gorga</surname><given-names>D</given-names></name><name><surname>Nagler</surname><given-names>W</given-names></name><name><surname>Goodwin</surname><given-names>C</given-names></name></person-group><article-title>Compliance with pressure garment use in burn rehabilitation</article-title><source>J Burn Care Rehab</source><year>1994</year><volume>15</volume><issue>2</issue><fpage>180</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1097/00004630-199403000-00015</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macintyre</surname><given-names>L</given-names></name><name><surname>Baird</surname><given-names>M</given-names></name></person-group><article-title>Pressure garments for use in the treatment of hypertrophic scars- a review of the problems associated with their use</article-title><source>Burns</source><year>2006</year><volume>32</volume><issue>1</issue><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.burns.2004.06.018</pub-id><pub-id pub-id-type="pmid">16413399</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>L</given-names></name><name><surname>Jones</surname><given-names>DJ</given-names></name></person-group><article-title>Silicone gel sheeting for preventing and treating hypertrophic and keloid scars</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>9</volume><fpage>CD003826</fpage><pub-id pub-id-type="pmid">24030657</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>K</given-names></name><name><surname>Umraw</surname><given-names>N</given-names></name><name><surname>Scott</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>K</given-names></name><name><surname>Musgrave</surname><given-names>M</given-names></name><name><surname>Cartotto</surname><given-names>R</given-names></name></person-group><article-title>Effects of enhanced patient education on compliance with silicone gel sheeting and burn scar outcome: a randomised prospective study</article-title><source>J Burn Care Rehabi</source><year>2003</year><volume>24</volume><issue>6</issue><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1097/01.BCR.0000095516.98523.04</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>EH</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name></person-group><article-title>Regulation of Transforming growth factor &#x003b2;1, platelet-derived growth factor, and basic fibroblast growth factor by silicone gel sheeting in early-stage scarring</article-title><source>Arch Plast Surg</source><year>2015</year><volume>42</volume><issue>1</issue><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.5999/aps.2015.42.1.20</pub-id><pub-id pub-id-type="pmid">25606485</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauglitz</surname><given-names>GG</given-names></name></person-group><article-title>Management of keloids and hypertrophic scars: current and emerging options</article-title><source>Clin Cosment Investig Dermatol</source><year>2013</year><volume>6</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.2147/CCID.S35252</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roques</surname><given-names>C</given-names></name><name><surname>T&#x000e9;ot</surname><given-names>L</given-names></name></person-group><article-title>The use of corticosteroids to treat keloids.: A review</article-title><source>Int J of Low Extrem Wounds</source><year>2008</year><volume>7</volume><issue>3</issue><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1177/1534734608320786</pub-id><pub-id pub-id-type="pmid">18611924</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manuskiatti</surname><given-names>W</given-names></name><name><surname>Fitzpatrixk</surname><given-names>RE</given-names></name></person-group><article-title>Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585&#x000a0;nm flashlamp-pumped pulse dye laser treatments</article-title><source>Arch Dermatol</source><year>2002</year><volume>138</volume><issue>9</issue><fpage>1149</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.1001/archderm.138.9.1149</pub-id><pub-id pub-id-type="pmid">12224975</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tredget</surname><given-names>EE</given-names></name><name><surname>Levi</surname><given-names>B</given-names></name><name><surname>Donelan</surname><given-names>MB</given-names></name></person-group><article-title>Biology and principles of scar management and burn reconstruction</article-title><source>Surg Clin North Am</source><year>2014</year><volume>94</volume><issue>4</issue><fpage>793</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.suc.2014.05.005</pub-id><pub-id pub-id-type="pmid">25085089</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabello</surname><given-names>FB</given-names></name><name><surname>Souza</surname><given-names>CD</given-names></name><name><surname>J&#x000fa;nior</surname><given-names>JAF</given-names></name></person-group><article-title>Update on hypertrophic scar treatment</article-title><source>Clinics</source><year>2014</year><volume>69</volume><issue>8</issue><fpage>565</fpage><lpage>573.55</lpage><pub-id pub-id-type="doi">10.6061/clinics/2014(08)11</pub-id><pub-id pub-id-type="pmid">25141117</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>S-J</given-names></name><name><surname>Chen</surname><given-names>J-Y</given-names></name><name><surname>Rahman</surname><given-names>K</given-names></name><name><surname>Hai-Liang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Medicinal plants for the treatment of hypertrophic scars</article-title><source>Evid Based Complement Alternat Med</source><year>2015</year><volume>2015</volume><fpage>101340</fpage><pub-id pub-id-type="pmid">25861351</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>JA</given-names></name><name><surname>Kasum</surname><given-names>CM</given-names></name></person-group><article-title>Dietary flavonoids: bioavailability, metabolic effects, and safety</article-title><source>Annu Rev Nutr</source><year>2002</year><volume>22</volume><fpage>19</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1146/annurev.nutr.22.111401.144957</pub-id><pub-id pub-id-type="pmid">12055336</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bors</surname><given-names>W</given-names></name><name><surname>Heller</surname><given-names>W</given-names></name><name><surname>Michel</surname><given-names>C</given-names></name><name><surname>Saran</surname><given-names>M</given-names></name></person-group><article-title>Flavonoids as antioxidants: Determination of radical-scavenging efficiencies</article-title><source>Methods Enzymol</source><year>1990</year><volume>186</volume><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/0076-6879(90)86128-I</pub-id><pub-id pub-id-type="pmid">2172711</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamson</surname><given-names>DW</given-names></name><name><surname>Brignall</surname><given-names>MS</given-names></name></person-group><article-title>Antioxidants and cancer, part 3: Quercetin</article-title><source>Altern Med Rev</source><year>2000</year><volume>5</volume><fpage>196</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">10869101</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prior</surname><given-names>RL</given-names></name></person-group><article-title>Fruits and vegetables in the prevention of cellular oxidative damage</article-title><source>Am J Clin Nutr</source><year>2003</year><volume>78</volume><fpage>570</fpage><lpage>8S</lpage></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RJ</given-names></name><name><surname>Spencer</surname><given-names>JP</given-names></name><name><surname>Rice-Evans</surname><given-names>C</given-names></name></person-group><article-title>Flavonoids: antioxidants or signalling molecules?</article-title><source>Free Radic Biol Med</source><year>2004</year><volume>36</volume><issue>7</issue><fpage>838</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2004.01.001</pub-id><pub-id pub-id-type="pmid">15019969</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>S</given-names></name><name><surname>Prasain</surname><given-names>J</given-names></name><name><surname>D&#x02019;Alessandro</surname><given-names>T</given-names></name><name><surname>Arabshahi</surname><given-names>A</given-names></name><name><surname>Botting</surname><given-names>N</given-names></name><name><surname>Lila</surname><given-names>MA</given-names></name><etal/></person-group><article-title>The metabolism and analysis of isoflavones and other dietary polyphenols in foods and biological systems</article-title><source>Food Function</source><year>2011</year><volume>2</volume><issue>5</issue><fpage>235</fpage><pub-id pub-id-type="doi">10.1039/c1fo10025d</pub-id><pub-id pub-id-type="pmid">21779561</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>TT</given-names></name><name><surname>Lim</surname><given-names>IJ</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Tan</surname><given-names>EK</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><name><surname>Longaker</surname><given-names>MT</given-names></name></person-group><article-title>Suppression of transforming growth factor beta/smad signalling in keloid derived fibroblasts by querectin; implications for the treatment of excessive scars</article-title><source>J Trauma</source><year>2004</year><volume>57</volume><issue>5</issue><fpage>1032</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1097/01.TA.0000114087.46566.EB</pub-id><pub-id pub-id-type="pmid">15580028</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>TT</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Tran</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Suppression of insulin like growth factor signalling pathway and collagen expression in keloid derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids</article-title><source>Br J Dermatol</source><year>2003</year><volume>148</volume><issue>3</issue><fpage>544</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2003.05174.x</pub-id><pub-id pub-id-type="pmid">12653748</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>FQ</given-names></name></person-group><article-title>Influence of quercetin and xray on collagen synthesis of cultured human keloid fibroblasts</article-title><source>Chin Med Sci J</source><year>2006</year><volume>21</volume><issue>3</issue><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">17086741</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>TT</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Bay</surname><given-names>BH</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name></person-group><article-title>Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar derived fibroblasts in vitro: therapeutic implications for excessive scarring</article-title><source>J Trauma</source><year>2003</year><volume>54</volume><issue>6</issue><fpage>1212</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1097/01.TA.0000030630.72836.32</pub-id><pub-id pub-id-type="pmid">12813346</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saulis</surname><given-names>AS</given-names></name><name><surname>Mogford</surname><given-names>JH</given-names></name><name><surname>Mustoe</surname><given-names>TA</given-names></name></person-group><article-title>Effect of Mederma on hypertrophic scarring in the rabbit ear model</article-title><source>Plast Recontr Surg</source><year>2002</year><volume>110</volume><issue>1</issue><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1097/00006534-200207000-00029</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augusti</surname><given-names>T</given-names></name></person-group><article-title>Therapeutic values of onion (Allium cepa L.) and garlic (Allium sativum L.)</article-title><source>Indian J Exp Biol</source><year>1996</year><volume>34</volume><issue>7</issue><fpage>634</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">8979497</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J-W</given-names></name><name><surname>Cho</surname><given-names>S-Y</given-names></name><name><surname>Lee</surname><given-names>S-R</given-names></name><name><surname>Lee</surname><given-names>K-S</given-names></name></person-group><article-title>Onion extract and quercetin induce matrix metalloproteinase &#x02212;1 in vitro and in vivo</article-title><source>Int J Mol Med</source><year>2010</year><volume>25</volume><fpage>347</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">20127038</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanprapaph</surname><given-names>K</given-names></name><name><surname>Tanrattanakorn</surname><given-names>S</given-names></name><name><surname>Wattanakrai</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effectiveness of onion extract gel on surgical scars in Asians</article-title><source>Dermatol Res Pract</source><year>2012</year><volume>2012</volume><fpage>212945</fpage><pub-id pub-id-type="pmid">22924037</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>WS</given-names></name><name><surname>Ying</surname><given-names>SY</given-names></name><name><surname>Chan</surname><given-names>PC</given-names></name><name><surname>Chan</surname><given-names>HH</given-names></name></person-group><article-title>Use of onion extract, heparin, allantoin gel in prevention of scarring in Chinese patients having laser removal of tattoos: A prospective randomized controlled trial</article-title><source>Dermatol Surg</source><year>2006</year><volume>32</volume><issue>7</issue><fpage>891</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">16875470</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wananukul</surname><given-names>S</given-names></name><name><surname>Chatpreodprai</surname><given-names>S</given-names></name><name><surname>Peongsujarit</surname><given-names>D</given-names></name><name><surname>Lertsapcharoen</surname><given-names>P</given-names></name></person-group><article-title>A prospective placebo-controlled study on the efficacy of onion extract in silicone derivative gel for the prevention of hypertrophic scar and keloid in median sternotomy wound in pediatric patients</article-title><source>J Med Assoc Thai</source><year>2013</year><volume>96</volume><issue>11</issue><fpage>1428</fpage><lpage>1433</lpage><pub-id pub-id-type="pmid">24428092</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenwitheesuk</surname><given-names>K</given-names></name><name><surname>Surakunprapha</surname><given-names>P</given-names></name><name><surname>Jenwitheesuk</surname><given-names>K</given-names></name><name><surname>Kuptamond</surname><given-names>C</given-names></name><name><surname>Prathanee</surname><given-names>S</given-names></name><name><surname>Intanoo</surname><given-names>W</given-names></name></person-group><article-title>Role of silicone derivative plus onion extract gel in presternal hypertrophic scar protection: a prospective randomized, double blinded, controlled trial</article-title><source>Int Wound J</source><year>2012</year><volume>9</volume><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1111/j.1742-481X.2011.00898.x</pub-id><pub-id pub-id-type="pmid">22168750</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beuth</surname><given-names>J</given-names></name><name><surname>Hunzelmann</surname><given-names>N</given-names></name><name><surname>van Leendert</surname><given-names>R</given-names></name><name><surname>Basten</surname><given-names>R</given-names></name><name><surname>Noehle</surname><given-names>M</given-names></name><name><surname>Schenider</surname><given-names>B</given-names></name></person-group><article-title>Safety and Efficacy of Local Administration of Contractubex&#x000ae; to Hypertrophic Scars in Comparison to Corticosteroid Treatment. Results of a Multicenter, Comparative Epidemiological Cohort Study in Germany</article-title><source>In vivo</source><year>2006</year><volume>20</volume><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">16634531</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Srivastava</surname><given-names>AK</given-names></name><name><surname>Bhui</surname><given-names>K</given-names></name><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Chaturvedi</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Resveratrol and Black Tea Polyphenol Combination Synergistically Suppress Mouse Skin Tumors Growth by Inhibition of Activated MAPKs and p53</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e23395</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0023395</pub-id><pub-id pub-id-type="pmid">21887248</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiroto</surname><given-names>Y</given-names></name><name><surname>Tadokoro</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>T</given-names></name><name><surname>Nakazono</surname><given-names>E</given-names></name><name><surname>Ohnaka</surname><given-names>K</given-names></name><name><surname>Takayanagi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Resveratrol, a phytoestrogen found in red wine, down-regulates protein S expression in HepG2 cells</article-title><source>Thrombo Res</source><year>2011</year><volume>127</volume><fpage>e1</fpage><lpage>e7</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2010.09.010</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>ER</given-names></name><name><surname>Naugle</surname><given-names>JE</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Bomser</surname><given-names>JA</given-names></name><name><surname>Meszaros</surname><given-names>JG</given-names></name></person-group><article-title>Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2005</year><volume>288</volume><issue>3</issue><fpage>1131</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00763.2004</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glehr</surname><given-names>M</given-names></name><name><surname>Fritsch-Breisach</surname><given-names>M</given-names></name><name><surname>Lohberger</surname><given-names>B</given-names></name><name><surname>Walzer</surname><given-names>SM</given-names></name><name><surname>Moazedi-Fuerst</surname><given-names>F</given-names></name><name><surname>Rinner</surname><given-names>B</given-names></name><etal/></person-group><article-title>Influence of resveratrol on rheumatoid fibroblast-like synoviocytes analysed with gene chip transcription</article-title><source>Phytomedicine</source><year>2013</year><volume>20</volume><issue>3&#x02013;4</issue><fpage>310</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2012.09.020</pub-id><pub-id pub-id-type="pmid">23137833</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>YX</given-names></name><name><surname>Xun</surname><given-names>AY</given-names></name><name><surname>Zeng</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis</article-title><source>Arch Med Res</source><year>2010</year><volume>41</volume><issue>4</issue><fpage>288</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2010.05.002</pub-id><pub-id pub-id-type="pmid">20637373</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>G</given-names></name><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name></person-group><article-title>Resveratrol mediated reduction of collagen by inhibiting proliferation and producing apoptosis in human hypertrophic scar fibroblasts</article-title><source>Biosci Biotechnol Biochem</source><year>2013</year><volume>77</volume><issue>12</issue><fpage>2389</fpage><lpage>2396</lpage><pub-id pub-id-type="doi">10.1271/bbb.130502</pub-id><pub-id pub-id-type="pmid">24317052</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sogutlu</surname><given-names>G</given-names></name><name><surname>Karabulut</surname><given-names>AB</given-names></name><name><surname>Ara</surname><given-names>C</given-names></name><name><surname>Cinpolat</surname><given-names>O</given-names></name><name><surname>Isik</surname><given-names>B</given-names></name><name><surname>Piskin</surname><given-names>T</given-names></name><etal/></person-group><article-title>The effect of resveratrol on surgery induced peritoneal adhesions in an experimental model</article-title><source>Cell Biochem Funct</source><year>2007</year><volume>25</volume><issue>2</issue><fpage>217</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1002/cbf.1324</pub-id><pub-id pub-id-type="pmid">16615042</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Torigoe</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Yotsuyanag</surname><given-names>T</given-names></name></person-group><article-title>Resveratrol inhibits fibrogenesis and induces apoptosis in keloid fibroblasts</article-title><source>Wound Repair Regen</source><year>2013</year><volume>21</volume><fpage>616</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1111/wrr.12062</pub-id><pub-id pub-id-type="pmid">23815229</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Branford OA, Grobbelaar AO, Rolfe KJ. Epigallocatechin-3-gallate (EGCG), a constituent of green tea and its anti-fibrotic effect. In Tea Consumption and Health Nova. 153&#x02013;166.</mixed-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>S</given-names></name><name><surname>Isemura</surname><given-names>M</given-names></name></person-group><article-title>Epigallocatechin-3-O-gallate inhibits fibroblast contraction of floating collagen gel: Interaction between epigallocatechin-3-O-gallate and platelet derived growth factor</article-title><source>Biosci Biotechnol Biochem</source><year>2004</year><volume>68</volume><fpage>1817</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1271/bbb.68.1817</pub-id><pub-id pub-id-type="pmid">15322374</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klass</surname><given-names>BR</given-names></name><name><surname>Branford</surname><given-names>OA</given-names></name><name><surname>Grobbelaar</surname><given-names>AO</given-names></name><name><surname>Rolfe</surname><given-names>KJ</given-names></name></person-group><article-title>The effect of epigallocatechin-3-gallate, a constituent of green tea, on transforming growth factor-beta1-stimulated wound contraction</article-title><source>Wound Repair Regen</source><year>2010</year><volume>18</volume><issue>1</issue><fpage>80</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1524-475X.2009.00552.x</pub-id><pub-id pub-id-type="pmid">20002896</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>AA</given-names></name><name><surname>Neuhaus</surname><given-names>T</given-names></name><name><surname>Skach</surname><given-names>RA</given-names></name><name><surname>Hatcheller</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>HY</given-names></name><name><surname>Schr&#x000f6;r</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mechanisms of the inhibitory effects of epigalocatechin-3 gallate on platelet &#x02013;derived growth factor-BB induced cell signalling and mitogenesis</article-title><source>FASEB J</source><year>2004</year><volume>18</volume><fpage>128</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">14630705</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>TT</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Geng</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>EGCG inhibits CTGF expression via blocking NF- &#x003ba;B activation in cardiac fibroblast</article-title><source>Phytomedicine</source><year>2013</year><volume>20</volume><issue>2</issue><fpage>106</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2012.10.002</pub-id><pub-id pub-id-type="pmid">23141425</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Deng</surname><given-names>YT</given-names></name><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Liu</surname><given-names>CM</given-names></name><name><surname>Chang</surname><given-names>HH</given-names></name><name><surname>Wong</surname><given-names>MY</given-names></name></person-group><article-title>Epigallocatechin-3-gallate inhibits lysophosphatidic acid-stimulated connective tissue growth factor via JNK and Smad3 suppression in human gingival fibroblasts</article-title><source>J Formos Med Assoc</source><year>2014</year><volume>223</volume><issue>1</issue><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2012.04.004</pub-id><pub-id pub-id-type="pmid">24445011</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moyle</surname><given-names>CW</given-names></name><name><surname>Cerezo</surname><given-names>AB</given-names></name><name><surname>Winterborne</surname><given-names>MS</given-names></name><name><surname>Hollands</surname><given-names>WJ</given-names></name><name><surname>Alexeev</surname><given-names>Y</given-names></name><name><surname>Needs</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Potent inhibition of VEGFR-2 activation by tight binding of green tea epigallocatechin gallate and apple procyanidins to VEGF: relevance to angiogenesis</article-title><source>Mol Nutr Food Res</source><year>2015</year><volume>59</volume><issue>3</issue><fpage>401</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201400478</pub-id><pub-id pub-id-type="pmid">25546248</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kawazoe</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>DW</given-names></name><name><surname>Matsumara</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Enhanced wound healing by an epigallocatechin gallate incorporated collagen sponge in diabetic mice</article-title><source>Wound Repair Regen</source><year>2008</year><volume>16</volume><fpage>714</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1111/j.1524-475X.2008.00422.x</pub-id><pub-id pub-id-type="pmid">19128267</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goo</surname><given-names>HC</given-names></name><name><surname>Hwang</surname><given-names>YS</given-names></name><name><surname>Choi</surname><given-names>YR</given-names></name><name><surname>Cho</surname><given-names>HN</given-names></name><name><surname>Suh</surname><given-names>H</given-names></name></person-group><article-title>Development of collagenase-resistant collagen and its interaction with adult human dermal fibroblasts</article-title><source>Biomaterials</source><year>2003</year><volume>24</volume><fpage>5099</fpage><lpage>5113</lpage><pub-id pub-id-type="doi">10.1016/S0142-9612(03)00431-9</pub-id><pub-id pub-id-type="pmid">14568426</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Ku</surname><given-names>SK</given-names></name><name><surname>Song</surname><given-names>KS</given-names></name><name><surname>Bae</surname><given-names>JS</given-names></name></person-group><article-title>Anti-inflammatory activities of oleanolic acid on HMGB1 activated HUVECs</article-title><source>Food Chem Toxicol</source><year>2012</year><volume>50</volume><issue>5</issue><fpage>1288</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2012.02.026</pub-id><pub-id pub-id-type="pmid">22386814</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravarti</surname><given-names>B</given-names></name><name><surname>Maurya</surname><given-names>R</given-names></name><name><surname>Siddiqui</surname><given-names>JA</given-names></name><name><surname>Bid</surname><given-names>HK</given-names></name><name><surname>Rajendran</surname><given-names>SM</given-names></name><name><surname>Yadav</surname><given-names>PP</given-names></name><etal/></person-group><article-title>In vitro anti-breast cancer activity of ethanolic extract of <italic>Wrightiato mentosa</italic>: role of pro-apoptotic effects of oleanolic acid and urosolic acid</article-title><source>J Ethnopharmacol</source><year>2012</year><volume>142</volume><issue>1</issue><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.04.015</pub-id><pub-id pub-id-type="pmid">22855944</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>XQ</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>JG</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>LP</given-names></name></person-group><article-title>Oleanolic acid inhibits hypertrophic scarring in the rabbit ear model</article-title><source>Clin Exp Dermatol</source><year>2011</year><volume>36</volume><issue>5</issue><fpage>528</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2230.2010.04012.x</pub-id><pub-id pub-id-type="pmid">21392079</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>YP</given-names></name><name><surname>Zhang</surname><given-names>LK</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>K</given-names></name><etal/></person-group><article-title>Curative effects of oleanolic acid on formed hypertrophic scars in the rabbit ear model</article-title><source>Evid Based Complement Alternat Med</source><year>2012</year><volume>2012</volume><fpage>2012837581</fpage></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>Y</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Tonosaki</surname><given-names>K</given-names></name><name><surname>Fujisawa</surname><given-names>S</given-names></name></person-group><article-title>Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analogue, alphadiisoeugenol</article-title><source>Anticancer Res</source><year>2005</year><volume>25</volume><fpage>4029</fpage><lpage>4036</lpage><pub-id pub-id-type="pmid">16309195</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>WH</given-names></name><name><surname>Wu</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name></person-group><article-title>Dosage effects of curcumin on cell death types in a human osteoblast cell line</article-title><source>Food Chem Toxicol</source><year>2006</year><volume>44</volume><fpage>1362</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2006.03.001</pub-id><pub-id pub-id-type="pmid">16624471</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dujic</surname><given-names>J</given-names></name><name><surname>Kippenberger</surname><given-names>S</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Ramirez-Bosca</surname><given-names>A</given-names></name><name><surname>Miguel</surname><given-names>J</given-names></name><name><surname>Diaz-Alperi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light</article-title><source>J Invest Dermatol</source><year>2007</year><volume>127</volume><fpage>1992</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700801</pub-id><pub-id pub-id-type="pmid">17410200</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panchatcharam</surname><given-names>M</given-names></name><name><surname>Miriyala</surname><given-names>S</given-names></name><name><surname>Gayathr</surname><given-names>VS</given-names></name><name><surname>Suguna</surname><given-names>L</given-names></name></person-group><article-title>Curcumin improves wound healing by modulating collagen and decreasing reactive oxygen species</article-title><source>Mol Cell Biochem</source><year>2006</year><volume>290</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s11010-006-9170-2</pub-id><pub-id pub-id-type="pmid">16770527</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scharstuhl</surname><given-names>A</given-names></name><name><surname>Mutsaers</surname><given-names>HAM</given-names></name><name><surname>Pennings</surname><given-names>SW</given-names></name><name><surname>Szarek</surname><given-names>WA</given-names></name><name><surname>Russel</surname><given-names>FG</given-names></name><name><surname>Wagener</surname><given-names>FA</given-names></name></person-group><article-title>Curcumin-induced fibroblast apoptosis and in vitro wound contraction are regulated by antioxidants and heme oxygenase: implications for scar formation</article-title><source>J Cell Mol Med</source><year>2009</year><volume>13</volume><issue>4</issue><fpage>712</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2008.00339.x</pub-id><pub-id pub-id-type="pmid">18410527</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Yin</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>Shikonin and its derivatives: a patent review</article-title><source>Expert Opin Ther Pat</source><year>2012</year><volume>22</volume><fpage>977</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1517/13543776.2012.709237</pub-id><pub-id pub-id-type="pmid">22834677</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fabritius</surname><given-names>MIC</given-names></name></person-group><article-title>Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer</article-title><source>Cancer Biol Ther</source><year>2009</year><volume>8</volume><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.4161/cbt.8.2.7087</pub-id><pub-id pub-id-type="pmid">19182512</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JT</given-names></name><name><surname>Li</surname><given-names>ZL</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Lu</surname><given-names>FJ</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name></person-group><article-title>An oxidative stress mechanism of shikonin in human glioma cells</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e94180</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0094180</pub-id><pub-id pub-id-type="pmid">24714453</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>IC</given-names></name><name><surname>Huang</surname><given-names>YJ</given-names></name><name><surname>Chiang</surname><given-names>CW</given-names></name><name><surname>Yeh</surname><given-names>LS</given-names></name></person-group><article-title>Shikonin induces apoptosis through reactive oxygen species/extracellular signal- regulated kinase pathway in osteosarcoma cells</article-title><source>Biol Pharm Bull</source><year>2010</year><volume>33</volume><fpage>816</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1248/bpb.33.816</pub-id><pub-id pub-id-type="pmid">20460760</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Aiuchi</surname><given-names>S</given-names></name><name><surname>Nakajo</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Beta-hydroxyisoovaleryishikonin inhibits the cell growth of various cancer cell lines and induces apoptosis in leukemia HL-60cells through a mechanism different from those of Fas and etoposide</article-title><source>J Biochem</source><year>1999</year><volume>125</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a022255</pub-id><pub-id pub-id-type="pmid">9880790</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Hiromura</surname><given-names>M</given-names></name><name><surname>Yasui</surname><given-names>H</given-names></name><name><surname>Sakurai</surname><given-names>H</given-names></name></person-group><article-title>Direct reaction between Shikonin and thiols induces apoptosis in HL60 cells</article-title><source>Biol Pharm</source><year>2002</year><volume>25</volume><fpage>827</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1248/bpb.25.827</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Upton</surname><given-names>Z</given-names></name></person-group><article-title>Investigating the potential of Shikonin as a novel hypertrophic scar treatment</article-title><source>J Biomed Sci</source><year>2015</year><volume>22</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.1186/s12929-015-0172-9</pub-id><pub-id pub-id-type="pmid">26275605</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Lynam</surname><given-names>E</given-names></name><name><surname>Leavesley</surname><given-names>DI</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><etal/></person-group><article-title>Functional and mechanistic investigation of Shikonin in scarring</article-title><source>Chemico-Bio Interact</source><year>2015</year><volume>228</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2014.12.037</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Leavesley</surname><given-names>D</given-names></name><etal/></person-group><article-title>Shikonin reduces TGF-&#x003b2;1- induced collagen production and contraction in hypertrophic scar derived fibroblasts</article-title><source>Int J Mole Med</source><year>2015</year><volume>36</volume><fpage>985</fpage><lpage>991</lpage></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhong</surname><given-names>XG</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Zhang</surname><given-names>SJ</given-names></name><name><surname>Gao</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Protective effect of emodin against airway inflammation in the ovlbumin-induced mouse model</article-title><source>Chin J Integr Med</source><year>2015</year><volume>21</volume><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1007/s11655-014-1898-z</pub-id><pub-id pub-id-type="pmid">25519442</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>K</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name></person-group><article-title>Therapeutic effect of emodin on collagen-induced arthritis in mice</article-title><source>Inflammation</source><year>2013</year><volume>36</volume><fpage>1253</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1007/s10753-013-9663-6</pub-id><pub-id pub-id-type="pmid">23729279</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YP</given-names></name><name><surname>Liu</surname><given-names>JP</given-names></name></person-group><article-title>Blockade of emodin on amyloid-&#x003b2; 26-35-induced neurotoxicity in A&#x003b2;PP/PS1 mice and PC12 cells through activation of the class III phosphatidylinositol 3-kinase/Beclin-1/B cells lymphoma 2 pathway</article-title><source>Planta Med</source><year>2015</year><volume>81</volume><fpage>108</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1055/s-0035-1556288</pub-id><pub-id pub-id-type="pmid">25590369</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirmali</surname><given-names>D</given-names></name><name><surname>Shanmugam</surname><given-names>MK</given-names></name><name><surname>Kumar</surname><given-names>AP</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>BK</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name></person-group><article-title>Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer</article-title><source>Cancer Lett</source><year>2013</year><volume>341</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.08.023</pub-id><pub-id pub-id-type="pmid">23962559</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>Inhibition of mechanical stress-induced hypertrophic scar inflammation by emodin</article-title><source>Molec Med Reports</source><year>2015</year><volume>11</volume><fpage>4087</fpage><lpage>4092</lpage></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Noor</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>YF</given-names></name><name><surname>Hylands</surname><given-names>PJ</given-names></name><name><surname>Simmonds</surname><given-names>MS</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>In vitro anti fibrotic activities of herbal compounds and herbs</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>3033</fpage><lpage>3041</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfp245</pub-id><pub-id pub-id-type="pmid">19474275</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>XH</given-names></name><name><surname>Sun</surname><given-names>RS</given-names></name><name><surname>Hu</surname><given-names>JM</given-names></name><name><surname>Mo</surname><given-names>ZF</given-names></name><name><surname>Yang</surname><given-names>ZF</given-names></name><name><surname>Jin</surname><given-names>GY</given-names></name><etal/></person-group><article-title>Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice</article-title><source>Clin Exp Pharmacol Physiol</source><year>2009</year><volume>36</volume><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2008.05048.x</pub-id><pub-id pub-id-type="pmid">18785980</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>MX</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>YB</given-names></name><name><surname>Li</surname><given-names>CC</given-names></name><name><surname>Geng</surname><given-names>YT</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group><article-title>Emodin protects rat liver from CCI(4) &#x02013; induced fibrogenesis via inhibition of hepatic stellate cells activation</article-title><source>World J Gastroenterol</source><year>2009</year><volume>15</volume><fpage>4753</fpage><lpage>4762</lpage><pub-id pub-id-type="doi">10.3748/wjg.15.4753</pub-id><pub-id pub-id-type="pmid">19824107</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepartz</surname><given-names>AI</given-names></name><name><surname>Subers</surname><given-names>NH</given-names></name></person-group><article-title>Catalase in honey</article-title><source>J Apic Res</source><year>1996</year><volume>5</volume><fpage>37</fpage><lpage>43</lpage></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subrahmanyam</surname><given-names>M</given-names></name></person-group><article-title>Addition of antioxidant and polyethylene glycol 4000 enhances the healing property of honey in burns</article-title><source>Ann Burns Fire Disasters</source><year>1996</year><volume>9</volume><fpage>93</fpage><lpage>95</lpage></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>NF</given-names></name><name><surname>Molan</surname><given-names>PC</given-names></name><name><surname>Harfoot</surname><given-names>CG</given-names></name></person-group><article-title>The sensitivity of dermatophytes to the antimicrobial activity of manuka honey and other honey</article-title><source>Pharm Sci</source><year>1997</year><volume>2</volume><fpage>1</fpage><lpage>3</lpage></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahdan</surname><given-names>H</given-names></name></person-group><article-title>Causes of the antimicrobial activity of honey</article-title><source>Infection</source><year>1998</year><volume>26</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/BF02768748</pub-id><pub-id pub-id-type="pmid">9505176</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Carter</surname><given-names>DA</given-names></name><name><surname>Turnbull</surname><given-names>L</given-names></name><name><surname>Rosendale</surname><given-names>D</given-names></name><name><surname>Hedderley</surname><given-names>D</given-names></name><name><surname>Stephens</surname><given-names>J</given-names></name><etal/></person-group><article-title>The Effect of New Zealand Kanuka, Manuka and Clover Honeys on Bacterial Growth Dynamics; and Cellular Morphology Varies According to the Species</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>55898</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0055898</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rufian-Henares</surname><given-names>JA</given-names></name><name><surname>Morales</surname><given-names>FJ</given-names></name></person-group><article-title>Functional properties of melanoidins: In vitro antioxidant, antimicrobial and antihypertensive activities</article-title><source>Food Res Int</source><year>2007</year><volume>40</volume><fpage>995</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1016/j.foodres.2007.05.002</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavric</surname><given-names>E</given-names></name><name><surname>Wittmann</surname><given-names>S</given-names></name><name><surname>Barth</surname><given-names>G</given-names></name><name><surname>Henle</surname><given-names>T</given-names></name></person-group><article-title>Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (<italic>Leptospermum scoparium)</italic> honeys from New Zealand</article-title><source>Mol Nutr Food Res</source><year>2008</year><volume>52</volume><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1002/mnfr.200700282</pub-id><pub-id pub-id-type="pmid">18210383</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwakman</surname><given-names>PHS</given-names></name><name><surname>teVelde</surname><given-names>AA</given-names></name><name><surname>de Boer</surname><given-names>L</given-names></name><name><surname>Spejer</surname><given-names>D</given-names></name><name><surname>Vandenbroucke-Grauls</surname><given-names>CM</given-names></name><name><surname>Zaat</surname><given-names>SA</given-names></name></person-group><article-title>How honey kills bacteria</article-title><source>FASEB J</source><year>2010</year><volume>24</volume><fpage>2576</fpage><lpage>2582</lpage><pub-id pub-id-type="doi">10.1096/fj.09-150789</pub-id><pub-id pub-id-type="pmid">20228250</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subrahmanyam</surname><given-names>M</given-names></name><name><surname>Hemmady</surname><given-names>A</given-names></name><name><surname>Pawar</surname><given-names>SG</given-names></name></person-group><article-title>The sensitivity to honey of multidrug-resistant Pseudomonas Aeruginosa from infected burns</article-title><source>Ann Burns Fire Disasters</source><year>2003</year><volume>16</volume><fpage>84</fpage><lpage>86</lpage></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abuharfeil</surname><given-names>N</given-names></name><name><surname>Al-Oran</surname><given-names>R</given-names></name><name><surname>Abo-Shehada</surname><given-names>M</given-names></name></person-group><article-title>The effect of bee honey on the proliferative activity of human B- and T-lymphocytes and the activity of phagocytes</article-title><source>Food Agric Immunol</source><year>1999</year><volume>11</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1080/09540109999843</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonks</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>RA</given-names></name><name><surname>Price</surname><given-names>AJ</given-names></name><name><surname>Molan</surname><given-names>PC</given-names></name><name><surname>Jones</surname><given-names>KP</given-names></name></person-group><article-title>Stimulation of TNF-alpha release in monocytes by honey</article-title><source>Cytokine</source><year>2001</year><volume>14</volume><fpage>240</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1006/cyto.2001.0868</pub-id><pub-id pub-id-type="pmid">11448125</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonks</surname><given-names>AJ</given-names></name><name><surname>Cooper</surname><given-names>RA</given-names></name><name><surname>Jones</surname><given-names>KP</given-names></name><name><surname>Blair</surname><given-names>S</given-names></name><name><surname>Parton</surname><given-names>J</given-names></name><name><surname>Tanks</surname><given-names>A</given-names></name></person-group><article-title>Honey stimulates inflammatory cytokine production from monocytes</article-title><source>Cytokine</source><year>2003</year><volume>21</volume><fpage>242</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/S1043-4666(03)00092-9</pub-id><pub-id pub-id-type="pmid">12824009</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molan</surname><given-names>PC</given-names></name></person-group><article-title>The evidence supporting the use of honey as a wound dressing</article-title><source>Int J Low Extrem Wounds</source><year>2006</year><volume>5</volume><fpage>40</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1177/1534734605286014</pub-id><pub-id pub-id-type="pmid">16543212</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Fuwano</surname><given-names>S</given-names></name><name><surname>Hayahi</surname><given-names>N</given-names></name><name><surname>Kinoshita</surname><given-names>A</given-names></name><name><surname>Miyahara</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of three types of Japanese honey on full thickness wound in mice</article-title><source>Evid Based Complement Alternat Med</source><year>2013</year><volume>2013</volume><fpage>504537</fpage><pub-id pub-id-type="pmid">23401714</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SS</given-names></name><name><surname>Singh</surname><given-names>O</given-names></name><name><surname>Bhagel</surname><given-names>PS</given-names></name><name><surname>Moses</surname><given-names>S</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Mathur</surname><given-names>RK</given-names></name></person-group><article-title>Honey dressing versus silver sulfadiazine dressing for wound healing in burn patients: a retrospective study</article-title><source>J Cutan Surg</source><year>2011</year><volume>4</volume><issue>3</issue><fpage>183</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.4103/0974-2077.91249</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jull</surname><given-names>AB</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>N</given-names></name></person-group><article-title>Honey as a topical treatment for wounds</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><volume>4</volume><fpage>CD005083</fpage><pub-id pub-id-type="pmid">18843679</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasiak</surname><given-names>J</given-names></name><name><surname>Cleland</surname><given-names>H</given-names></name><name><surname>Campbell</surname><given-names>F</given-names></name></person-group><article-title>Dressings for superficial and partial thickness burns</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><volume>8</volume><issue>4</issue><fpage>CD002106</fpage><pub-id pub-id-type="pmid">18843629</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storm-Versloot</surname><given-names>MN</given-names></name><name><surname>Vos</surname><given-names>CG</given-names></name><name><surname>Ubbink</surname><given-names>DT</given-names></name><name><surname>Vermeulen</surname><given-names>H</given-names></name></person-group><article-title>Topical silver for preventing wound infection</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><volume>17</volume><issue>3</issue><fpage>CD006478</fpage><pub-id pub-id-type="pmid">20238345</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subrahmanyam</surname><given-names>M</given-names></name></person-group><article-title>Honey impregnated gauze versus polyurethane film (OpSiteR) in the treatment of burns &#x02013; a prospective randomised study</article-title><source>Br J Plast Surg</source><year>1993</year><volume>46</volume><fpage>322</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/0007-1226(93)90012-Z</pub-id><pub-id pub-id-type="pmid">8330089</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subrahmanyam</surname><given-names>M</given-names></name></person-group><article-title>Honey impregnated gauze versus amniotic membrane in the treatment of burns</article-title><source>Burns</source><year>1994</year><volume>20</volume><fpage>331</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/0305-4179(94)90061-2</pub-id><pub-id pub-id-type="pmid">7945822</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subrahmanyam</surname><given-names>M</given-names></name></person-group><article-title>A prospective randomised clinical and histopathological study of superficial burn wound healing with honey and silver sulfadiazine</article-title><source>Burns</source><year>1998</year><volume>24</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/S0305-4179(97)00113-7</pub-id><pub-id pub-id-type="pmid">9625243</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y-F</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>KC</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Klaassen</surname><given-names>CD</given-names></name></person-group><article-title>Oleanolic acid alters bile acid metabolism and produces cholestatic liver injury in mice</article-title><source>Toxicol Appl Pharmacol</source><year>2013</year><volume>272</volume><fpage>10.1016</fpage></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>MP</given-names></name><name><surname>Reisman</surname><given-names>SA</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>O'Grady</surname><given-names>M</given-names></name><name><surname>Linde</surname><given-names>PG</given-names></name><name><surname>McCullough</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl</article-title><source>Am J Nephrol</source><year>2014</year><volume>39</volume><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1159/000362906</pub-id><pub-id pub-id-type="pmid">24903467</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>HH</given-names></name><name><surname>Garland</surname><given-names>LL</given-names></name><name><surname>Heckman-Stoddard</surname><given-names>BM</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Butler</surname><given-names>VD</given-names></name><etal/></person-group><article-title>A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones</article-title><source>J Transl Med</source><year>2014</year><volume>12</volume><fpage>223</fpage><pub-id pub-id-type="doi">10.1186/s12967-014-0223-0</pub-id><pub-id pub-id-type="pmid">25115686</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovera</surname><given-names>J</given-names></name><name><surname>Ramos</surname><given-names>A</given-names></name><name><surname>Devier</surname><given-names>D</given-names></name><name><surname>Garrison</surname><given-names>V</given-names></name><name><surname>Kovner</surname><given-names>B</given-names></name><name><surname>Reza</surname><given-names>T</given-names></name><etal/></person-group><article-title>Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies</article-title><source>J Neurol Sci</source><year>2015</year><volume>358</volume><fpage>46</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2015.08.006</pub-id><pub-id pub-id-type="pmid">26298797</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillukat</surname><given-names>MH</given-names></name><name><surname>Bester</surname><given-names>C</given-names></name><name><surname>Hensel</surname><given-names>A</given-names></name><name><surname>Lechtenberg</surname><given-names>M</given-names></name><name><surname>Petereit</surname><given-names>F</given-names></name><name><surname>Beckebaum</surname><given-names>S</given-names></name><etal/></person-group><article-title>Concentrated green tea extract induces severe acute hepatitis in a 63-year-old woman--a case report with pharmaceutical analysis</article-title><source>J Ethnopharmacol</source><year>2014</year><volume>155</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2014.05.015</pub-id><pub-id pub-id-type="pmid">24862489</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vohra</surname><given-names>S</given-names></name><name><surname>Cvijovic</surname><given-names>K</given-names></name><name><surname>Boon</surname><given-names>H</given-names></name><name><surname>Foster</surname><given-names>BC</given-names></name><name><surname>Jaeger</surname><given-names>W</given-names></name><name><surname>LeGatt</surname><given-names>D</given-names></name><etal/></person-group><article-title>Study of natural health product reactions (SPNAR): Active surveillance of adverse events following the concurrent natural health product and prescription use in community pharmacies</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>9</issue><fpage>e45196</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0045196</pub-id><pub-id pub-id-type="pmid">23028841</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bun</surname><given-names>SS</given-names></name><name><surname>Ciccolini</surname><given-names>J</given-names></name><name><surname>Bun</surname><given-names>H</given-names></name><name><surname>Aubert</surname><given-names>C</given-names></name><name><surname>Catalin</surname><given-names>J</given-names></name></person-group><article-title>Drug interactions of paclitaxel metabolism in human liver microsomes</article-title><source>J Chemother</source><year>2003</year><volume>15</volume><fpage>266</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1179/joc.2003.15.3.266</pub-id><pub-id pub-id-type="pmid">12868554</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sak</surname><given-names>K</given-names></name></person-group><article-title>Chemotherapy and dietary phytocemical agents</article-title><source>Chem Res Practice</source><year>2012</year><volume>2012</volume><fpage>282570</fpage></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name></person-group><article-title>The interactions of anticancer agents with tea catechins: current evidence from preclinical studies</article-title><source>Anticancer Agents Med Chem</source><year>2014</year><volume>14</volume><fpage>1343</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.2174/1871520614666140829123651</pub-id><pub-id pub-id-type="pmid">25173560</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CZ</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>WX</given-names></name><name><surname>Ni</surname><given-names>M</given-names></name><name><surname>Mehendale</surname><given-names>S</given-names></name><etal/></person-group><article-title>Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells</article-title><source>Cancer Chemother Pharmacol</source><year>2007</year><volume>60</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s00280-006-0350-2</pub-id><pub-id pub-id-type="pmid">17009031</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>331</volume><fpage>1245</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.04.044</pub-id><pub-id pub-id-type="pmid">15883009</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boocock</surname><given-names>DJ</given-names></name><name><surname>Faust</surname><given-names>GE</given-names></name><name><surname>Patel</surname><given-names>KR</given-names></name><name><surname>Schinas</surname><given-names>AM</given-names></name><name><surname>Brown</surname><given-names>VA</given-names></name><name><surname>Ducharme</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2007</year><volume>16</volume><fpage>1246</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-0022</pub-id><pub-id pub-id-type="pmid">17548692</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>FA</given-names></name><name><surname>Wu</surname><given-names>AB</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name><name><surname>Kang</surname><given-names>JJ</given-names></name><name><surname>Cheng</surname><given-names>HW</given-names></name></person-group><article-title>Effect of hydroxypropyl-&#x003b2;-cyclodextrin on the solubility, photo stability and in vitro permeability of alkannin/shikonin enantiomers</article-title><source>Int J Pharm</source><year>1996</year><volume>141</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(96)04634-0</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Gui</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo</article-title><source>Biosci Rep</source><year>2013</year><volume>33</volume><fpage>e00020</fpage><pub-id pub-id-type="doi">10.1042/BSR20120065</pub-id><pub-id pub-id-type="pmid">23176403</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olthof</surname><given-names>MR</given-names></name><name><surname>Hollman</surname><given-names>PCH</given-names></name><name><surname>Vree</surname><given-names>TB</given-names></name><name><surname>Katan</surname><given-names>MB</given-names></name></person-group><article-title>Bioavailabilities of quercetin-3-glucoside and quercetin-4&#x02019;-glucoside do not differ in humans</article-title><source>J Nutr</source><year>2000</year><volume>130</volume><fpage>1200</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">10801919</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiesewetter</surname><given-names>H</given-names></name><name><surname>Koscielny</surname><given-names>J</given-names></name><name><surname>Kalus</surname><given-names>U</given-names></name><name><surname>Vix</surname><given-names>JM</given-names></name><name><surname>Petrini</surname><given-names>O</given-names></name><name><surname>van Toor</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial</article-title><source>Arzneimittelforschung</source><year>2000</year><volume>50</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">10719612</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erlund</surname><given-names>I</given-names></name><name><surname>Kosonen</surname><given-names>T</given-names></name><name><surname>Alfthan</surname><given-names>J</given-names></name><name><surname>M&#x000e4;enp&#x000e4;&#x000e4;</surname><given-names>J</given-names></name><name><surname>Pertunen</surname><given-names>K</given-names></name><name><surname>Kenraali</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers</article-title><source>Eur J Clin Pharmaol</source><year>2000</year><volume>56</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1007/s002280000197</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombardi</surname><given-names>G</given-names></name><name><surname>Vannini</surname><given-names>S</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name><name><surname>Marcotullio</surname><given-names>MC</given-names></name><name><surname>Dominici</surname><given-names>L</given-names></name><name><surname>Villarini</surname><given-names>M</given-names></name><etal/></person-group><article-title>In Vitro Safety/Protection Assessment of Resveratrol and Pterostilbene in a Human Hepatoma Cell Line (HepG2)</article-title><source>Nat Prod Commum</source><year>2015</year><volume>10</volume><fpage>1403</fpage><lpage>1408</lpage></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>RS</given-names></name><name><surname>Thomas</surname><given-names>RG</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Mintzer</surname><given-names>J</given-names></name><name><surname>Reynolds</surname><given-names>BA</given-names></name><etal/></person-group><article-title>A randomised double-blind, placebo controlled trial of resveratrol for Alzheimer disease</article-title><source>Neurology</source><year>2015</year><volume>85</volume><fpage>1383</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002035</pub-id><pub-id pub-id-type="pmid">26362286</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Made</surname><given-names>SM</given-names></name><name><surname>Plat</surname><given-names>J</given-names></name><name><surname>Mensink</surname><given-names>RP</given-names></name></person-group><article-title>Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0118393</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0118393</pub-id><pub-id pub-id-type="pmid">25790328</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joe</surname><given-names>AK</given-names></name><name><surname>Schnol-Sussman</surname><given-names>F</given-names></name><name><surname>Bresailier</surname><given-names>RS</given-names></name><name><surname>Abrams</surname><given-names>JA</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Cheung</surname><given-names>K</given-names></name><etal/></person-group><article-title>Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus</article-title><source>Cancer Prev Res</source><year>2015</year><volume>8</volume><fpage>1131</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-14-0274-T</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><mixed-citation publication-type="other">Chen IJ, Liu CY, Chiu JP, Hsu CH. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2015; in press</mixed-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>HH</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Hamkim</surname><given-names>IA</given-names></name><name><surname>Crowell</surname><given-names>JA</given-names></name><name><surname>Shahi</surname><given-names>F</given-names></name><name><surname>Brooks</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>3312</fpage><lpage>3319</lpage><pub-id pub-id-type="pmid">12960117</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><mixed-citation publication-type="other">Zhao H, Zhu W, Jia L, Sun X, Chen G, Zhao X, et al. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy. Br J Radiol. In press</mixed-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dostal</surname><given-names>AM</given-names></name><name><surname>Samavat</surname><given-names>H</given-names></name><name><surname>Bedell</surname><given-names>S</given-names></name><name><surname>Trokelson</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Swenson</surname><given-names>K</given-names></name><etal/></person-group><article-title>The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial</article-title><source>Food Chem Toxicol</source><year>2015</year><volume>83</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2015.05.019</pub-id><pub-id pub-id-type="pmid">26051348</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mdhluli</surname><given-names>MC</given-names></name><name><surname>van der Horst</surname><given-names>G</given-names></name></person-group><article-title>The effect of oleanolic acid on sperm motion characteristics and fertility of male Wistar rats</article-title><source>Lab Anim</source><year>2002</year><volume>36</volume><fpage>432</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1258/002367702320389107</pub-id><pub-id pub-id-type="pmid">12396287</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Phase I clinical trial of curcumin, a chemo preventative agent, in patients with high-risk or pre-malignant lesions</article-title><source>Anticancer Res</source><year>2001</year><volume>21</volume><fpage>2895</fpage><lpage>2900</lpage><pub-id pub-id-type="pmid">11712783</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goeal</surname><given-names>A</given-names></name><name><surname>Kunnumakkara</surname><given-names>AB</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Curcumin as &#x02018;Curemin&#x02019;: from kitchen to clinic</article-title><source>Biochem Pharmacol</source><year>2008</year><volume>75</volume><fpage>787</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2007.08.016</pub-id><pub-id pub-id-type="pmid">17900536</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Wilkinson</surname><given-names>J</given-names></name><name><surname>Di</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Hatcher</surname><given-names>H</given-names></name><name><surname>Kock</surname><given-names>ND</given-names></name><etal/></person-group><article-title>Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>462</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-05-155952</pub-id><pub-id pub-id-type="pmid">18815282</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albreht</surname><given-names>A</given-names></name><name><surname>Vovk</surname><given-names>I</given-names></name><name><surname>Simonovska</surname><given-names>B</given-names></name></person-group><article-title>Addition of &#x003b2;-lactoglobulin produces water-soluble shikonin</article-title><source>J Agric Food Chem</source><year>2012</year><volume>60</volume><fpage>10834</fpage><lpage>10843</lpage><pub-id pub-id-type="doi">10.1021/jf303153d</pub-id><pub-id pub-id-type="pmid">22998586</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Long-term systemic toxicity of shikonin derivatives in Wistar rats</article-title><source>Pharm Biol</source><year>2014</year><volume>52</volume><fpage>486</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.3109/13880209.2013.846913</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>Traynor</surname><given-names>K</given-names></name><name><surname>Santos</surname><given-names>K</given-names></name><name><surname>Blaser</surname><given-names>G</given-names></name><name><surname>Bode</surname><given-names>U</given-names></name><name><surname>Molan</surname><given-names>P</given-names></name></person-group><article-title>Medical Honey for Wound Care&#x02014;Still the &#x02018;Latest Resort&#x02019;?</article-title><source>Evid Based Complement Alternat Med</source><year>2009</year><volume>6</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1093/ecam/nem175</pub-id><pub-id pub-id-type="pmid">18955301</pub-id></element-citation></ref></ref-list></back></article>